[{"Abstract":"<b>Background:<\/b> Lung cancer is the leading cause of cancer death worldwide. Tumor recurrence is the most common cause of treatment failure after surgical resection. The S100 protein family is a multigenic group of cytoplasmic calcium-binding proteins. S100A16 has to be reported to be an independent prognostic indicator of poor overall survival in lung adenocarcinoma recently. However, the prognostic value of S100A16 in recurrence-free survival (RFS) in patients with resected lung adenocarcinoma has not been well demonstrated. The relationship between S100A16 expression and the histological subtypes of lung adenocarcinoma remained unknown.<br \/><b>Methods:<\/b> A total of 79 patients with resected lung adenocarcinoma were included in the study. S100A16 expression was determined by immunohistochemistry in tumor specimens. The prognostic value of S100A16 overexpression and its relationship with clinicopathological variables, including histology subtypes, were investigated.<br \/><b>Results:<\/b> S100A16 overexpression tended to be significantly associated with order age (<i>P<\/i> = 0.074). There was no significant association between S100A16 overexpression and predominant pattern group (lepidic\/acinar\/papillary vs. micropapillary\/solid) (<i>P<\/i> = 0.447). Univariate analysis indicated that pathologic stage (II or III vs. I) (<i>P <\/i>= 0.001) and S100A16 overexpression (<i>P <\/i>= 0.005) were significant prognostic factors for worse recurrence-free survival (RFS). Predominant pattern group (lepidic\/acinar\/papillary vs. micropapillary\/solid) (<i>P <\/i>= 0.064) tended to be a significant prognostic factor for worse RFS. In multivariate analysis, pathologic stage (II or III vs. I) (HR, 27.847; 95% CI, 4.173 to 185.831; <i>P <\/i>= 0.001), and S100A16 overexpression (HR, 21.740; 95% CI, 2.516 to 187.870; <i>P <\/i>= 0.005) were still significant prognostic factors for worse RFS.<br \/><b>Conclusions:<\/b> S100A16 overexpression was a significant prognostic factor for worse RFS in patients with resected lung adenocarcinoma. This information is useful to stratify high-risk patients of recurrence after resection of lung adenocarcinoma.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Lung cancer: non-small cell,S100A16,Prognosis,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>J.-J. Hung<\/b>; <br\/>National Yang Ming Chiao Tung University and Taipei Veterans General Hospital, Taipei, Taiwan","CSlideId":"","ControlKey":"008cd844-d3d5-4461-9125-0d366a6b8b1e","ControlNumber":"6983","DisclosureBlock":"&nbsp;<b>J. Hung, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2406","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7640","PresenterBiography":null,"PresenterDisplayName":"Jung-Jyh Hung, MD;PhD","PresenterKey":"b69a2bd4-7602-4d5a-aee3-83a0095f81d9","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7640. Prognostic significance of S100A16 expression in patients with resected lung adenocarcinoma","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Prognostic significance of S100A16 expression in patients with resected lung adenocarcinoma","Topics":null,"cSlideId":""},{"Abstract":"<b><u>Background:<\/u> <\/b>An accurate prognostic algorithm based on germline whole exome sequencing (WES) would complement tumor omics as a non-invasive source of biomarkers for guiding cancer patient therapy. In a previous study, we used WES and RNA-seq data from muscle-invasive bladder cancer (MIBC) and normal host cells to train a survival model, wherein we discovered that mutated germline genes accounted for 90% of feature importance. We have since defined a larger cohort to identify key germline biomarkers of overall survival (OS) that may be scalable for application in the clinic.<br \/><b><u>Methods<\/u>: <\/b>169 patients from The Cancer Genome Atlas (TCGA) with MIBC stages T2-T4 that underwent radical cystectomy (RC) w\/o neoadjuvant treatment were eligible. OS at 4 years was the primary clinical endpoint as it is associated with death due to metastatic tumor recurrence. Patients were dichotomized to <i>control <\/i>survivors who were alive at 4+ years, and <i>cases <\/i>who died within 4 years but no less than 4 months after RC. 49 qualifying survivors were propensity matched against 49 dead patients by stage, adjuvant treatment, gender, race, and age. The remaining 71 dead patients served as a holdout. Only high (e.g. frameshift) and moderate (e.g. indel) impact germline variants were included. Mutations were weighted for allele frequency (penalize common) and genotype (reward homozygous) before grouping at the gene level. A panel of the 21 most differential genes in stratified patients were selected for neural network training using AIQC. The model forced protective\/ pathogenic genes to interact and produced individual survival probabilities. Gene importance was determined via permutation.<br \/><b><u>Results<\/u>: <\/b>OS was accurately predicted for 98.2% of patients: 1 FN, 2 FP, 37 TN, 119 TP. The top 3 permuted genes (and related pathways) were: SORL1 (A&#946;), KIF27 (hedgehog), CUL7 (p53). The most differential gene was CUL7: 31% of survivors mutated vs 2% of dead.<br \/><b><u>Conclusion<\/u>:<\/b> Neural network analysis identified the promise of germline genetics as an accurate predictor of survival and tumor recurrence in MIBC patients. Upon validation in an external cohort, these biomarkers could be used to inform adjuvant therapy and complement molecular residual disease alongside circulating tumor (ct)-DNA.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Bladder cancer,Genetic factors,Prognostic markers,Deep learning,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>G. P. Sonpavde<\/b><sup>1<\/sup>, A. H. Nassar<sup>2<\/sup>, A. Ravi<sup>3<\/sup>, L. Sadler<sup>4<\/sup>; <br\/><sup>1<\/sup>AdventHealth Cancer Institute, Orlando, FL, <sup>2<\/sup>Yale Cancer Center, New Haven, CT, <sup>3<\/sup>Dana-Farber Cancer Institute, Boston, MA, <sup>4<\/sup>KeyBio, Boston, MA","CSlideId":"","ControlKey":"bca98b38-f1f1-41b8-9519-0ee4becbed40","ControlNumber":"8465","DisclosureBlock":"<b>&nbsp;G. P. Sonpavde, <\/b> <br><b>BMS<\/b> Other, consultant. <br><b>Seagen<\/b> Other, speaker, advisory board. <br><b>Merck<\/b> Other, consultant. <br><b>Astellas<\/b> Other, speaker. <br><b>Gilead<\/b> Grant\/Contract, Other, speaker, advisory board. <br><b>Loxo<\/b> Other, advisory board. <br><b>EMD Serono<\/b> Grant\/Contract, Other. <br><b>Jazz Pharma<\/b> Grant\/Contract, Other. <br><b>Myriad<\/b> Employment, Other, spouse employment. <br><b>Natera<\/b> Other, speaker. <br><b>Exelixis<\/b> Other, speaker. <br><b>Janssen<\/b> Other, speaker. <br><b>Bicycle Therapeutics<\/b> Other. <br><b>G1 Therapeutics<\/b> Other, consultant. <br><b>Servier<\/b> Other, consultant. <br><b>Aveo<\/b> Other, speaker. <br><b>Bayer<\/b> Other, speaker. <br><b>Mereo<\/b> Other, Data safety monitoring board. <br><b>A. H. Nassar, <\/b> <br><b>PRIME CENTER<\/b> Grant\/Contract. <br><b>Veterans Health Adminstration<\/b> Grant\/Contract. <br><b>Onclive<\/b> Other, speaker. <br><b>Tempus<\/b> Other, honorarium. <br><b>KSMO<\/b> Other, honorarium. <br><b>Guidepoint<\/b> consultant. <br><b>A. Ravi, <\/b> <br><b>KeyBio<\/b> Other, consultant. <br><b>Halo solutions<\/b> Stock, Other, consultant. <br><b>IBM<\/b> Grant\/Contract. <br><b>L. Sadler, <\/b> <br><b>KeyBio<\/b> Employment.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2407","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7641","PresenterBiography":null,"PresenterDisplayName":"Guru Sonpavde, MD","PresenterKey":"dfa2f733-f4f5-4e68-9ba3-e88ebcbcec8a","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7641. Prognostic impact of functional germline mutations in muscle-invasive bladder cancer identified by neural network analysis","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Prognostic impact of functional germline mutations in muscle-invasive bladder cancer identified by neural network analysis","Topics":null,"cSlideId":""},{"Abstract":"The majority of patients with bladder cancer initially present with non-muscle-invasive disease (NMIBC). While NMIBC may be cured with transurethral resection +\/- intravesical therapies, approximately 20% of patients develop progression to muscle-invasive bladder cancer (MIBC) which requires life-altering treatments such as cystectomy and has a high risk of lethal metastatic recurrence. Current risk stratification for NMIBC relies on clinicopathologic features that overlook the potential role of the tumor microenvironment (TME) in bladder cancer pathogenesis. We sought to delineate the stromal and immune landscape alterations within the TME upon bladder cancer progression and to identify TME-related features that could enhance current prognostic approaches. Analyzing by single-cell RNA sequencing and multiplexed imaging of 22 untreated NMIBC and MIBC specimens, coupled with publicly available datasets, we discovered significant transcriptional variability among cancer-associated fibroblasts (CAFs) and macrophages across patients. This inter-patient variability was attributable to the extensive remodeling of these cell types during cancer progression. Notably, a specific subset of CAF, characterized by ITGA8+F3+ markers, was found to be highly enriched in NMIBC lesions and transcriptionally related to sub-urothelial fibroblasts of the healthy bladder, whereas a FAP+ CAF subset enriched for core matrisome related genes was dominant in MIBC lesions. We developed a FAP+ CAF signature which was then projected onto a large public dataset of bulk-RNAseq data from patients with NMIBC demonstrating that the FAP+ CAF signature was significantly associated with progression to MIBC independently of contemporary risk stratification scores. The presence of FAP+ CAFs in a subset of NMIBC specimens was orthogonally validated using immunohistochemistry. Importantly, areas with FAP staining were observed in close contact with individual or small groups of tumor cells exhibiting an invasive phenotype and partial epithelial-mesenchymal transition, likely explaining the higher risk of progression to MIBC. Our study improves our understanding of fibroblasts remodeling during bladder cancer progression and highlights the potential of integrating CAF-derived biomarkers into NMIBC risk stratification models.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Bladder cancer,Biomarkers,Cancer-associated fibroblasts,Tumor progression,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>A. Abbas<\/b><sup>1<\/sup>, S. Maskey<sup>2<\/sup>, E. Cheng<sup>2<\/sup>, Z. Li<sup>3<\/sup>, K. Ganesh<sup>1<\/sup>, S. Izadmehr<sup>2<\/sup>, S. Janho dit Hreich<sup>1<\/sup>, B. Demaille<sup>1<\/sup>, J. Mesple<sup>1<\/sup>, P. Sirven<sup>1<\/sup>, C. Krucker<sup>4<\/sup>, J. Fontugne<sup>4<\/sup>, I. Bernard-Pierrot<sup>4<\/sup>, Y. Allory<sup>4<\/sup>, M. Merad<sup>2<\/sup>, J. Adam<sup>5<\/sup>, J. Sfakianos<sup>6<\/sup>, E. Kenigsberg<sup>2<\/sup>, M. Galsky<sup>3<\/sup>, H. Salmon<sup>1<\/sup>; <br\/><sup>1<\/sup>Institut Curie, INSERM, U932, Equipe Leader Fondation ARC, PSL Research University, Paris, France, <sup>2<\/sup>The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, <sup>3<\/sup>The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, <sup>4<\/sup>Institut Curie, CNRS, UMR144, Equipe labellis√©e Ligue Contre le Cancer, PSL Research University, Paris, France, <sup>5<\/sup>Department of Pathology, Paris Saint-Joseph Hospital, Paris, France, <sup>6<\/sup>Icahn School of Medicine at Mount Sinai, New York, NY","CSlideId":"","ControlKey":"b7e8da50-8e9d-487f-8b5f-1167c6ede4bf","ControlNumber":"6613","DisclosureBlock":"&nbsp;<b>A. Abbas, <\/b> None..<br><b>S. Maskey, <\/b> None..<br><b>E. Cheng, <\/b> None..<br><b>Z. Li, <\/b> None..<br><b>K. Ganesh, <\/b> None..<br><b>S. Izadmehr, <\/b> None..<br><b>S. Janho dit Hreich, <\/b> None..<br><b>B. Demaille, <\/b> None..<br><b>J. Mesple, <\/b> None..<br><b>P. Sirven, <\/b> None..<br><b>C. Krucker, <\/b> None..<br><b>J. Fontugne, <\/b> None..<br><b>I. Bernard-Pierrot, <\/b> None..<br><b>Y. Allory, <\/b> None..<br><b>M. Merad, <\/b> None..<br><b>J. Adam, <\/b> None..<br><b>J. Sfakianos, <\/b> None.&nbsp;<br><b>E. Kenigsberg, <\/b> <br><b>Genentech<\/b> Employment.<br><b>M. Galsky, <\/b> None..<br><b>H. Salmon, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2408","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7642","PresenterBiography":null,"PresenterDisplayName":"Abdenour ABBAS, PhD","PresenterKey":"0d56b721-ad5e-4c9d-95ae-fa3a8a529f0e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7642. Activated FAP+ cancer-associated fibroblasts in non-muscle invasive bladder cancer are associated with progression to muscle-invasive disease","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Activated FAP+ cancer-associated fibroblasts in non-muscle invasive bladder cancer are associated with progression to muscle-invasive disease","Topics":null,"cSlideId":""},{"Abstract":"<b>Background:<\/b> Pancreatic ductal adenocarcinoma (PDAC) stands out for its aggressive nature, often manifesting through invasion, metastasis, and recurrence. These characteristics are partly attributable to the Epithelial-mesenchymal transition (EMT), a critical phenomenon that follows the disintegration of epithelial barriers, including tight junctions (TJs), where Claudin (CLDN) proteins are integral components.<br \/><b>Objective:<\/b> This study focused on elucidating the differential expression of claudins in PDAC and exploring their correlations with disease progression, invasiveness, and immune infiltration.<br \/><b>Methodology:<\/b> Utilizing UCSC TOIL RNA-seq, TCGA-PAAD genomic, and clinical data, we investigated the genomic alterations and differential expression of claudins in PDAC. Conducted survival analysis using log-rank tests. Assessed immune infiltration patterns using the EPIC deconvolution algorithm.<br \/><b>Results:<\/b> Of 177 PDAC samples examined, 23 (13%) exhibited at least one form of claudin gene alteration, including mutations, amplifications, or deep deletions. Remarkably, 10 claudins (CLDN1, 2, 4, 5, 7, 11, 12, 15, 18, and 23) were found to be significantly overexpressed in PDAC samples, meeting a log2FC threshold of &#8805;1 (p &#60; 0.05). Further, we identified a direct correlation between mRNA expression and copy numbers, alongside an inverse relationship with methylation levels, particularly in CLDN1, CLDN12, CLDN15, CLDN23, and CLDN4. Intriguingly, claudin expression escalated from grades G1 to G3 but diminished in G4, with CLDN1, CLDN4, and CLDN7 showing significant variability (Kruskal-Wallis rank test p-values of 1.2E-5, 0.00064, and 0.023, respectively). Survival analysis indicated that high expression levels of CLDN1 and CLDN4 were linked to poorer patient outcomes, while higher levels of CLDN5 and CLDN15 correlated with improved survival (log-rank p-values of 0.007, 0.016, 0.0035, and 0.0012, respectively), findings consistent across both univariate and multivariate analyses. Furthermore, immune infiltration patterns, assessed via the EPIC deconvolution algorithm, varied significantly between high and low CLDN expression groups. Specifically, low CLDN1 expression was associated with increased presence of B-cells, CAF, and CD8<sup>+<\/sup> T-cells but fewer endothelial cells, a pattern reversed in high CLDN1 expression cases. A similar trend was observed for CLDN4.<br \/><b>Conclusion:<\/b> Our study underscores the significant prognostic value of claudin proteins in PDAC, highlighting their potential as indicators of disease progression and survival and their influence on the tumor's immune environment.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Pancreatic cancer,Prognostic markers,Bioinformatics,Cancer progression,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>A. A. Bhat<\/b><sup>1<\/sup>, S. Usmani<sup>1<\/sup>, H. Q. Sadida<sup>1<\/sup>, S. Hashem<sup>1<\/sup>, T. Masoodi<sup>1<\/sup>, I. Ahmed<sup>1<\/sup>, R. Kumar<sup>2<\/sup>, M. Singh<sup>3<\/sup>, P. Dhawan<sup>4<\/sup>, S. Uddin<sup>5<\/sup>, M. A. Macha<sup>6<\/sup>, A.-S. Akil<sup>1<\/sup>; <br\/><sup>1<\/sup>Sidra Medicine, DOHA, Qatar, <sup>2<\/sup>School of Biotechnology, Shri Mata Vaishno Devi University, Katra, Jammu and Kashmir, India, <sup>3<\/sup>All India Institute of Medical Sciences (AIIMS), New Delhi, India, <sup>4<\/sup>University of Nebraska Medical Center, Omaha, Omaha, NE, <sup>5<\/sup>Translational Research Institute, Academic Health System, Hamad Medical Corporation, DOHA, Qatar, <sup>6<\/sup>Watson-Crick Centre for Molecular Medicine, Islamic University of Science and Technology, Awantipora, Kashmir, India","CSlideId":"","ControlKey":"afeb1d1c-c284-41b2-8cf8-1b3bf166facf","ControlNumber":"6782","DisclosureBlock":"&nbsp;<b>A. A. Bhat, <\/b> None..<br><b>S. Usmani, <\/b> None..<br><b>H. Q. Sadida, <\/b> None..<br><b>S. Hashem, <\/b> None..<br><b>T. Masoodi, <\/b> None..<br><b>I. Ahmed, <\/b> None..<br><b>R. Kumar, <\/b> None..<br><b>M. Singh, <\/b> None..<br><b>P. Dhawan, <\/b> None..<br><b>S. Uddin, <\/b> None..<br><b>M. A. Macha, <\/b> None..<br><b>A. Akil, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2409","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7643","PresenterBiography":"","PresenterDisplayName":"Ajaz Bhat, PhD","PresenterKey":"f6e8fef5-e811-4585-a6da-08c96ab7d620","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7643. Prognostic significance and immune infiltration patterns related to Claudin heterogeneity in pancreatic ductal adenocarcinoma patients","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Prognostic significance and immune infiltration patterns related to Claudin heterogeneity in pancreatic ductal adenocarcinoma patients","Topics":null,"cSlideId":""},{"Abstract":"Residual cancer burden (RCB) based on pathologic characteristics is the most powerful prognostic factor in breast cancer (BC) which received neoadjuvant chemotherapy (NAC) followed by surgery. According to RCB classification, class III predicted short survival duration regardless of BC subtypes according to hormone receptor (HR) and human epidermal growth factor receptor-2 (HER-2) state. However, up to 20-40% of BCs with RCB class III did not experience BC recurrence and had long term survival without disease recurrence. In our study, we evaluated genomic characteristics of BC which had high RCB class. We collected 96 fresh frozen BC specimens which had undergone surgery after NAC between 2010 and 2018 from Samsung Medical Center Biobank. We performed whole genome or exome sequencing, RNA sequencing and high-plex single-cell spatial transcriptomics. Of 96 BCs, 65 BCs had experienced BC recurrence and 31 BCs have not been BC recurrence. Of 65 BCs with dismal prognosis, 12 were HR+HER2-, four in HR+HER2+, 39 in triple negative breast cancer (TNBC) and 10 in HR-HER2+ BC. Of 31 BCs without recurrence, 11 were HR+HER2-, two in HR+HER2+, 14 in TNBC and four in HR-HER2+ BC. In HR+HER2- BC, ten of 12 BCs with dismal prognosis were categorized into basal like intrinsic subtype and two were into luminal B subtype compared that six of luminal A and five of luminal B subtype categorization in good prognosis BC group. Age associated mutation signature were enriched in HR+HER2- BC with good prognosis (p=0.027). Tumor microenvironment (TME) analysis using Kassandra suggested that high monocytes were associated with BC with dismal prognosis (p=0.00031). In single-cell spatial transcriptome analysis, T-cell abundance in the tumoral niche is associated with dismal prognosis in HR+HER2- BC (p=0.039). In TNBC, almost BCs (88.7%) were categorized into basal-like intrinsic subtype regardless of their prognosis. TME analysis presented that immune cells including macrophages and lymphocytes with CD4 and CD8 T cells were significantly enriched in TNBC with good prognosis (ps &#60;0.05, respectively). In HER2+ BC, intrinsic subtypes were heterogeneous in both groups. Focal amplification in HER2+BC patient harbored DNA segments from different chromosomes more frequently than in those with good prognosis (p=0.00091), which was prominent in oncogenic extrachromosomal DNA amplifications compared to other oncogenic amplifications. In TME analysis, there were no specific cell enrichments according to BC prognosis but sing-cell spatial transcriptome analysis revealed that higher T-cell abundance in the tumoral niche was associated with HR+HER2+ BC with good prognosis (p=0.047). In conclusion, each BC subtype had their own genomic characteristics to determine their prognosis. Our study also suggested that TME characteristics was common prognostic factor for survival outcome of BC with residual tumor after NAC.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Breast cancer,Tumor microenvironment,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>J.-Y. Kim<\/b><sup>1<\/sup>, S. Park<sup>2<\/sup>, S. Ahn<sup>3<\/sup>, E. Seo<sup>4<\/sup>, S. Kim<sup>3<\/sup>, M. Gregory<sup>5<\/sup>, E. Killingbeck<sup>5<\/sup>, E. Cho<sup>1<\/sup>, J. Lee<sup>1<\/sup>, J. Ahn<sup>1<\/sup>, Y. Park<sup>1<\/sup>, W.-Y. Park<sup>4<\/sup>, H. Kim<sup>3<\/sup>, S. Lee<sup>2<\/sup>, Y.-H. Im<sup>1<\/sup>; <br\/><sup>1<\/sup>Samsung Medical Center, Seoul, Korea, Republic of, <sup>2<\/sup>Ulsan National Institute of Science and Technology, Ulsan, Korea, Republic of, <sup>3<\/sup>Sungkyunkwan University, Suwon, Korea, Republic of, <sup>4<\/sup>Samsung Genome Institute, Seoul, Korea, Republic of, <sup>5<\/sup>NanoString Technologies, Seattle, WA","CSlideId":"","ControlKey":"d9391a1e-f2a6-4dc6-a5ff-3646e4b749d1","ControlNumber":"5531","DisclosureBlock":"&nbsp;<b>J. Kim, <\/b> None..<br><b>S. Park, <\/b> None..<br><b>S. Ahn, <\/b> None..<br><b>E. Seo, <\/b> None..<br><b>S. Kim, <\/b> None..<br><b>M. Gregory, <\/b> None..<br><b>E. Killingbeck, <\/b> None..<br><b>E. Cho, <\/b> None..<br><b>J. Lee, <\/b> None..<br><b>J. Ahn, <\/b> None.&nbsp;<br><b>Y. Park, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Roche<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract. <br><b>Eisai Korea<\/b> Consultant. <br><b>Eli Lilly<\/b> Consultant. <br><b>Norvatis<\/b> Consultant. <br><b>W. Park, <\/b> <br><b>Genius.Inc.<\/b> Other Business Ownership.<br><b>H. Kim, <\/b> None..<br><b>S. Lee, <\/b> None..<br><b>Y. Im, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2410","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7644","PresenterBiography":null,"PresenterDisplayName":"Ji-Yeon Kim","PresenterKey":"637da9fc-1dad-4e6b-863d-deff252d70ea","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7644. Prognostication of genomic characteristics of residual breast cancer after neoadjuvant chemotherapy","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Prognostication of genomic characteristics of residual breast cancer after neoadjuvant chemotherapy","Topics":null,"cSlideId":""},{"Abstract":"Racial disparities in prostate cancer are prevalent, with African American (AA) men experiencing 60% greater incidence and 2 to 3 times higher mortality than Caucasian American (CA) men. Consequently, there is a pressing need for improved means of interrogating race\/ethnicity-based prostate cancer biology in order to identify biomarkers to help stratify men at high-risk for prostate cancer-specific progression and death and offer treatment recommendation that would mostly benefit AA men undergoing early aggressive therapies. Current predictive models rely on clinical variables but do not account for these disparities. The overall goal is to construct a race-specific prostate cancer prognostic prediction model for risk assessment. Here we performed comprehensive bioinformatics analysis using the data from 17 pairs of gene expression array from AA and CA cohorts and identified 63 differentially expressed genes (DEGs) by race. Among them, chemokine receptor 4 (CXCR4), viz. p-Akt (Ser473), fatty acid synthase (FASN), interleukin-6 (IL-6) and matrix metallopeptidase 9 (MMP-9) gene expressions were significantly altered in AA groups. Immunohistochemistry was performed on 163 prostate cancer patient specimens to validate DEG expression and immunoreactive scores (IRS) were calculated. CXCR4 exhibited significantly higher expression in AA tumors, with &#62; 85% of AA prostate tumors showing weak to strong CXCR4 expression, compared to &#60; 5% in CA specimens. While immunostaining for IL-6, FASN, MMP9 and p-Akt did not provide a significant distinction between CA and AA cases. IRS analysis confirmed higher expression of CXCR4 in AA cancers, compared to CA prostate cancer (p &#60; 0.001). MMP9 and IL6 expression were moderately higher in AA cancer compared to CA prostate cancer (p &#60; 0.05). In contrast, FASN expression was significantly higher in CA cancer, compared to AA prostate cancer (p &#60; 0.001). We further investigated the impact of these genes on biochemical recurrence-free survival (BCRFS) using Kaplan-Meier analysis to examine the differences between low-risk versus high-risk groups. BCRFS analysis demonstrated that CXCR4 is a determinant factor of recurrence risk in AA prostate cancer patients. The activation of the PI3K-Akt signaling pathway, particularly in AA patients, suggests its role in prostate cancer aggressiveness. Taken together, this study demonstrates the importance of differential expression of biomarkers which constitute the bulk tumors in driving cancer. The distinct gene expression patterns, especially the upregulation of CXCR4, in AA prostate cancer highlight its potential as a prognostic biomarker and a target for personalized treatment strategies. These findings encourage further study into the role of population-specific difference in adding CXCR4 in risk model construction, especially in machine learning models.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Prostate cancer,Biomarkers,Racial Disparity,Predictive biomarkers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"A. A. Ahmed, S. Verma, I. M. Atawia, D. L. Shen, G. T. MacLennan, P. Fu, <b>S. Gupta<\/b>; <br\/>Case Western Reserve University School of Medicine, Cleveland, OH","CSlideId":"","ControlKey":"6ee563c4-3a3c-41fb-81a8-3b3086054a32","ControlNumber":"1648","DisclosureBlock":"&nbsp;<b>A. A. Ahmed, <\/b> None..<br><b>S. Verma, <\/b> None..<br><b>I. M. Atawia, <\/b> None..<br><b>D. L. Shen, <\/b> None..<br><b>G. T. MacLennan, <\/b> None..<br><b>P. Fu, <\/b> None..<br><b>S. Gupta, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2411","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7645","PresenterBiography":null,"PresenterDisplayName":"Sanjay Gupta, PhD","PresenterKey":"334c15dd-e01c-4d5c-bfc4-5a90c81ba93c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7645. Differentially expressed genes as prognostic markers in racial disparities of prostate cancer","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Differentially expressed genes as prognostic markers in racial disparities of prostate cancer","Topics":null,"cSlideId":""},{"Abstract":"Background: Despite the promising potential of neoadjuvant immune checkpoint blockade (ICB) in ESCC, postoperative recurrence remains a critical challenge. Besides pathological response, there remains no biomarkers for recurrence risk prediction after neoadjuvant ICB. Recent studies have highlighted a strong association between ICB efficacy and tumor immune microenvironment (TIME). Thus, we sought to investigate the TIME features in surgically resected tumors following neoadjuvant ICB from patients with ESCC to develop a potential way for recurrence risk prediction.<br \/>Methods: This is a side study of a phase 2 NICE trial (ChiCTR1900026240) of 51 patients with resectable locally advanced ESCC who received neoadjuvant ICB plus chemotherapy followed by surgery from 2019 to 2020. TIME features of surgically resected tumors after neoadjuvant therapy were assessed by multiplex immunohistochemistry (mIHC) for immune markers (CD8, PD-L1, CD45RO, PD-1, Pan-CK, CD4, FoxP3, CD68, CD163). We first analyzed TIME features in tumors evaluated as pathological complete response (pCR) and major pathological response (MPR). Then, we divided 51 patients into a training and validation set; and machine learning was applied to identify a list of TIME features that predict recurrence-free survival (RFS) and to develop a TIME-based signature (TIS) on neoadjuvant ICB prognosis.<br \/>Results: Fifty-one patients from NICE trial were used for primary analysis. A higher positive rate of CD8<sup>+<\/sup> cells, CD163<sup>-<\/sup>CD68<sup>+<\/sup> macrophages and CD8<sup>+<\/sup>CD45RO<sup>+<\/sup> cells was observed in patients with pCR. Similarly, MPR patients exhibited a higher positive rate of CD8<sup>+<\/sup> cells and CD8<sup>+<\/sup>CD45RO<sup>+<\/sup> cells. Regarding RFS prediction, machine learning selection of TIS were identified: CD8<sup>+<\/sup>PD1<sup>-<\/sup>(cytotoxic T cells), CD4<sup>+<\/sup>Foxp3<sup>+<\/sup> (Treg), CD8<sup>+<\/sup>CD45RO<sup>+<\/sup> (memory T cells), and M1 macrophages (CD163<sup>-<\/sup>CD68<sup>+<\/sup>) exhibited significant predictive value. Stratifying patients into low- and high-risk groups using TIS for RFS revealed a prolonged prolonged RFS in the low-risk group (p&#60;0.001; HR: 0.08, 95% CI [0.03-0.25]). Notably, when applying TIS to pCR patients, we identified a subset of high-risk pCR patients (median RFS = 8.9 months, 1- year RFS=32%) relapsed earlier than low-risk pCR patients (median RFS = not reached, 1-year RFS=100%, p&#60;0.001). Multivariable Cox regression analysis demonstrated that TIS was an independent predictor for RFS as well as overall survival (both p&#60;0.001). Further independent validation (ICB and non-ICB cohort) of TIS is ongoing.<br \/>Conclusion: The establishment of a risk prediction model based on TIME demonstrated the potential to enhance postoperative monitoring management for ESCC patients who underwent surgery after neoadjuvant ICB. Our study provides insights into development of optimal post-immunotherapy management strategy.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Esophageal cancer,Immune checkpoint blockade,Recurrence,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>Z. Liu<\/b><sup>1<\/sup>, B. Yu<sup>1<\/sup>, Y. Yang<sup>1<\/sup>, C. Qi<sup>1<\/sup>, C. Yuan<sup>1<\/sup>, Y. Yang<sup>1<\/sup>, J. Wei<sup>1<\/sup>, S. Chen<sup>2<\/sup>, Y. Wang<sup>2<\/sup>, Z. Li<sup>1<\/sup>; <br\/><sup>1<\/sup>Shanghai Chest Hospital, Shanghai, China, <sup>2<\/sup>Virtue Diagnostics (Suzhou) Co., Ltd, Shanghai, China","CSlideId":"","ControlKey":"6463b753-bd6e-47f5-bc78-4111f5e6550a","ControlNumber":"4117","DisclosureBlock":"&nbsp;<b>Z. Liu, <\/b> None..<br><b>B. Yu, <\/b> None..<br><b>Y. Yang, <\/b> None..<br><b>C. Qi, <\/b> None..<br><b>C. Yuan, <\/b> None..<br><b>Y. Yang, <\/b> None..<br><b>J. Wei, <\/b> None..<br><b>S. Chen, <\/b> None..<br><b>Y. Wang, <\/b> None..<br><b>Z. Li, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2412","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"7","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7646","PresenterBiography":null,"PresenterDisplayName":"Zhichao Liu, MD","PresenterKey":"ad483ec0-bd98-4d9d-9ef5-33aadd883a6e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7646. Evaluation of tumor immune microenvironment after neoadjuvant immunotherapy in patients with esophageal squamous cell carcinoma (ESCC): Towards a prediction for recurrence risk","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Evaluation of tumor immune microenvironment after neoadjuvant immunotherapy in patients with esophageal squamous cell carcinoma (ESCC): Towards a prediction for recurrence risk","Topics":null,"cSlideId":""},{"Abstract":"Biomarker signatures associated with disease progression are important tools for the management of patient care. However, such signatures are frequently indication-specific, which limits their utility to stratify broader populations. Transcriptional plasticity, the ability of a transcriptome to change in response to external stimuli, is of interest due to its relation to disease progression and therapeutic response. To extend and generalize the measurement of a patient&#8217;s risk of disease progression to a pan-cancer, sequencing-based biomarker, Emax, the maximum cytotoxicity of a compound in a cell line, was explored as a potential universal marker of transcriptional plasticity.<br \/>To explore correlation between Emax and transcriptional plasticity, cancer cell lines were ranked by mean Emax across multiple classes of cytotoxic compounds analyzed in GDSC (Yang et. al., 2013). Cell lines with lower Emax (more surviving cells at high drug concentrations) were filtered to exclude cell lines which tended to have higher IC50 values to remove cell lines that may be generally more resistant. With GDSC1 as the train set and GDSC2 as the test set, differentially expressed genes between high-Emax and low-Emax cell lines were selected for further analysis and possible inclusion in the plasticity biomarker signature.<br \/>Test analysis in GDSC2 revealed an R2 of 0.88 suggesting transferability. For clinical validation, public repositories were queried for tumor RNA sequencing data with paired response data. To avoid batch effects between experiments, preliminary validation focused on one sufficiently large dataset with well-curated response data (n = 170; Barrett et. al., 2013, GSE91061; phs000452.v1.p1). Analysis of the expression of the genes identified in the in vitro signature revealed significant differential expression between patients who were reported as having an objective response and patients who achieved stable disease as best response. In silico pathway analysis of this signature revealed enrichment in cell-cell adhesion, signaling, and gene regulation, which relate to the hallmarks of phenotypic plasticity and epigenetic reprogramming (Hanahan, 2022).<br \/>This analysis reveals similarity between gene expression patterns associated with Emax measured in vitro and transcriptional plasticity in the clinic. Additional experimentation is underway to prospectively analyze this set of biomarkers and to retrospectively validate this signature in additional datasets with the goal of patient stratification by the risk of disease progression following an initial, incomplete response to therapy.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"RNA sequencing (RNA-Seq),Bioinformatics,Transcription,Pan-cancer biomarker,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>J. Goldstein<\/b>, C. Gavazzi, M. Grushko, M. Samizadeh, Z. ElSeht, K. Arline; <br\/>SHEPHERD Therapeutics, Boston, MA","CSlideId":"","ControlKey":"e7d5b234-ecde-4725-8433-42b6516fa756","ControlNumber":"5012","DisclosureBlock":"<b>&nbsp;J. Goldstein, <\/b> <br><b>SHEPHERD Therapeutics<\/b> Employment. <br><b>C. Gavazzi, <\/b> <br><b>SHEPHERD Therapeutics<\/b> Employment. <br><b>M. Grushko, <\/b> <br><b>SHEPHERD Therapeutics<\/b> Employment. <br><b>M. Samizadeh, <\/b> <br><b>SHEPHERD Therapeutics<\/b> Employment. <br><b>Z. ElSeht, <\/b> <br><b>SHEPHERD Therapeutics<\/b> Employment. <br><b>K. Arline, <\/b> <br><b>SHEPHERD Therapeutics<\/b> Employment.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2413","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"8","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7647","PresenterBiography":null,"PresenterDisplayName":"Mahta Samizadeh, PhD;Pharm D","PresenterKey":"93222218-f414-4ea8-865d-342c0a73c6bb","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7647. Identification of transcriptional plasticity biomarkers for patient stratification","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Identification of transcriptional plasticity biomarkers for patient stratification","Topics":null,"cSlideId":""},{"Abstract":"<b>Introduction and Objectives: <\/b>T1 high grade (T1HG) bladder cancer (BC) is a type of non-muscle invasive BC (NMIBC) that is recognized as an aggressive subtype with a heightened propensity for progression. Current risk stratification methods for NMIBC rely on clinicopathological indicators; however, these approaches do not adequately capture the aggressive nature of T1HG BC. Thus, new, more accurate biomarkers for T1HG risk stratification are needed. Here, we enrolled three different patient cohorts and investigated expression of <i>COL6A1<\/i>, a key component of the extracellular matrix, at different stages and grades of BC, with a specific focus on T1HG BC. <b>Materials and Methods: <\/b>Samples from 298 BC patients were subjected to RNA sequencing and real-time PCR. <b>Results: <\/b>We found that T1HG BC and muscle invasive BC (MIBC) exhibited comparable expression of <i>COL6A1<\/i>, which was significantly higher than that by other NMIBC subtypes. In particular, T1HG patients who later progressed to MIBC had considerably higher expression of <i>COL6A1<\/i> than Ta, T1 low-grade patients, and patients that did not progress, highlighting the aggressive nature and higher risk of progression associated with T1HG BC. Moreover, Cox and Kaplan-Meier survival analyses revealed a significant association between elevated expression of <i>COL6A1<\/i> and poor progression-free survival of T1HG BC patients (multivariate Cox hazard ratio, 16.812; 95% confidence interval, 3.283-86.095; P=0.001 and P=0.0002 [log-rank test]). <b>Conclusion: <\/b>These findings suggest that <i>COL6A1<\/i> may be a promising biomarker for risk stratification of T1HG BC, offering valuable insight into disease prognosis and guidance of personalized treatment decisions.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Progression,Non-muscle invasive bladder neoplasm,Collagen type &#8549;,T1 high grade,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>X.-M. Piao<\/b><sup>1<\/sup>, Y. Byun<sup>1<\/sup>, C.-M. Zheng<sup>1<\/sup>, S.-K. Kim<sup>2<\/sup>, S.-H. Park<sup>3<\/sup>, K. Min<sup>4<\/sup>, H. Park<sup>4<\/sup>, S. Moon<sup>5<\/sup>, K. Kim<sup>5<\/sup>, H. Kang<sup>5<\/sup>, W. Kim<sup>5<\/sup>, S. Yun<sup>5<\/sup>; <br\/><sup>1<\/sup>College of Medicine, Chungbuk National University, Cheongju, Korea, Republic of, <sup>2<\/sup>Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea, Republic of, <sup>3<\/sup>University of Science and Technology, Daejeon, Korea, Republic of, <sup>4<\/sup>Gwangju Institute of Science and Technology, Gwangju, Korea, Republic of, <sup>5<\/sup>Chungbuk National University Hospital, Cheongju, Korea, Republic of","CSlideId":"","ControlKey":"63f0e487-329e-4558-923e-52e835a21658","ControlNumber":"714","DisclosureBlock":"<b>&nbsp;X. Piao, <\/b> <br><b>National Research Foundation<\/b> Grant\/Contract, This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF), funded by the Ministry of Education (MOE) (No. 2021R1I1A1A01050891) and by the BK21 FOUR of the NRF funded by the Ministry of Education (No. 5199990614277).&nbsp;<br><b>Y. Byun, <\/b> <br><b>National Research Foundation<\/b> Grant\/Contract, This research was supported by Basic Science Research Program through the National Research Foundation, funded by the Ministry of Education (No. RS-2023-00245919).<br><b>C. Zheng, <\/b> None.&nbsp;<br><b>S. Kim, <\/b> <br><b>National Research Foundation<\/b> Grant\/Contract, This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation, funded by the Korean government (MSIT) (No. 2014M3C9A3068554, 2021M3H9A2096953, and 2022R1A2C2008480).. <br><b>Korea Research Institute of Bioscience and Biotechnology (KRIBB)<\/b> Grant\/Contract, This research was supported by a grant from the Korea Research Institute of Bioscience and Biotechnology (KRIBB) Research Initiative Program (KGM5192322).<br><b>S. Park, <\/b> None.&nbsp;<br><b>K. Min, <\/b> <br><b>Korea Health Industry Development Institute<\/b> Grant\/Contract, This research was supported by a grant of the MD-Phd\/Medical Scientist Training Program through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea.<br><b>H. Park, <\/b> None..<br><b>S. Moon, <\/b> None..<br><b>K. Kim, <\/b> None..<br><b>H. Kang, <\/b> None..<br><b>W. Kim, <\/b> None.&nbsp;<br><b>S. Yun, <\/b> <br><b>National Research Foundation<\/b> This research was supported by Basic Science Research Program through the NRF, funded by the Ministry of Education (MOE) (No.2020R1I1A3062508); and by \"Regional Innovation Strategy (RIS)\" through the NRF funded by the MOE (2021RIS-001); and by the BK21 FOUR of the NRF funded by the Ministry of Education (No. 5199990614277).. <br><b>Korea Health Industry Development Institute<\/b> Grant\/Contract, This research was supported by a grant of the MD-Phd\/Medical Scientist Training Program through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2414","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"9","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7648","PresenterBiography":null,"PresenterDisplayName":"Xuan-Mei Piao, MD,PhD","PresenterKey":"ec31ae52-8b24-4fea-98b1-c99e7e5d4670","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7648. COL6A1 expression as a potential prognostic biomarker for risk stratification of T1HG bladder cancer: Unveiling the aggressive nature of a distinct non-muscle invasive subtype","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"COL6A1 expression as a potential prognostic biomarker for risk stratification of T1HG bladder cancer: Unveiling the aggressive nature of a distinct non-muscle invasive subtype","Topics":null,"cSlideId":""},{"Abstract":"Background: Sarcopenia and inflammation are independent prognostic indicators of poor survival in lung cancer. Systemic inflammation contributes to sarcopenia or low muscle mass through increased catabolism and decreased synthesis of muscle protein. In turn, sarcopenia leads to inflammation in the muscle and exacerbation of systemic inflammation. Specific Aim: The aim of this study was to determine the association between sarcopenia and systemic biomarkers of inflammation including neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and albumin in diverse individuals with lung cancer and determine their use as prognostic indicators of sarcopenia. Methods: This retrospective cross-sectional study included 218 non-Hispanic Black (n=111) and White (n=107) individuals with lung cancer. Computed tomography scans were analyzed to calculate skeletal mass index (SMI) at the third lumbar vertebra. Sarcopenia was defined using published sex-specific criteria for SMI in healthy individuals then categorized into the binary variable of sarcopenia\/no sarcopenia. NLR, PLR, and albumin were analyzed as both continuous and categorical variables, with NLR<u>&#62;<\/u> 3, PLR <u>&#62;<\/u>150, and albumin &#60;3.5 defining moderate to high inflammation. T-tests, Mann Whitney U, Chi square, and adjusted Logistic Regression were used as appropriate. Results: Subjects presented with a mean age of 68.5 <u>+<\/u> 9.8 years, BMI of 26.3 <u>+<\/u> 5.9 kg\/m<sup>2<\/sup>, 50.9% non-Hispanic Black, and 49.5% female with significantly higher prevalence of late-stage lung cancer (61.9% versus 38.1% early-stage, p&#60;0.001) and no differences in age and BMI by race\/ethnicity. Mean NLR (6.2 <u>+<\/u> 7.2), PLR (226.9 <u>+<\/u> 157.9), and albumin (3.2 <u>+<\/u> 0.6) indicated an inflammatory state in diverse individuals with lung cancer, with significantly higher NLR (8.5 <u>+<\/u> 9.7 versus 4.7 <u>+<\/u> 4.2, p&#60;0.001) and PLR (268.9 <u>+<\/u> 204.5 versus 198.7 <u>+<\/u> 108.9, p&#60;0.01) and significantly lower albumin (3.1 <u>+<\/u> 0.7 versus 3.4 <u>+<\/u> 0.5, p&#60;0.01) in those with sarcopenia compared to those without sarcopenia. The odds of sarcopenia were 2.2 higher with NLR <u>&#62;<\/u> 3 compared to NLR &#60;3 (95% CI: 1.1, 4.4) and 2.5 higher with albumin &#60;3.5 compared to albumin <u>&#62;<\/u>3.5 (95% CI: 1.2, 5.3) after controlling for race\/ethnicity, stage of cancer, age, and BMI. PLR <u>&#62;<\/u> 150 was not a significant predictor of sarcopenia. Conclusion: Diverse individuals with sarcopenia of lung cancer present with higher inflammation compared to individuals with lung cancer but without sarcopenia as indicated by NLR, PLR, and albumin levels. Moderate to high levels of inflammation as indicated by high NLR and low albumin may help predict sarcopenia status in diverse individuals with lung cancer.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Inflammation,Lung cancer,Biomarkers,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>C. A. Byrne<\/b><sup>1<\/sup>, G. Fantuzzi<sup>1<\/sup>, V. M. Oddo<sup>1<\/sup>, S. Kim<sup>1<\/sup>, T. J. Koh<sup>1<\/sup>, S. L. Gomez<sup>2<\/sup>; <br\/><sup>1<\/sup>University of Illinois at Chicago, Chicago, IL, <sup>2<\/sup>Rush University, Chicago, IL","CSlideId":"","ControlKey":"cbb1db72-0cd5-4c92-af05-5bc014e5bfeb","ControlNumber":"2672","DisclosureBlock":"<b>&nbsp;C. A. Byrne, <\/b> <br><b>SEAGEN<\/b> Stock.<br><b>G. Fantuzzi, <\/b> None..<br><b>V. M. Oddo, <\/b> None..<br><b>S. Kim, <\/b> None..<br><b>T. J. Koh, <\/b> None..<br><b>S. L. Gomez, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2415","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"10","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7649","PresenterBiography":null,"PresenterDisplayName":"Cecily Byrne, PhD","PresenterKey":"b0cc4db6-8005-4769-bed6-b3cfecf6fac6","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7649. Inflammatory biomarkers by sarcopenia status in diverse individuals with lung cancer","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Inflammatory biomarkers by sarcopenia status in diverse individuals with lung cancer","Topics":null,"cSlideId":""},{"Abstract":"Introduction: Sarcopenia, progressive and generalized loss of skeletal muscle mass, is difficult and labor intensive to directly measure as it requires manual segmentations by radiologists from computed tomography (CT) scans. Sarcopenia has been shown to be a prognostic factor in some metastatic cancers. We evaluated the impact of sarcopenia derived via an automated segmentation algorithm on outcomes in the Phase 3 NSCLC clinical trial, CheckMate 227 (NCT02477826)<br \/>Methods: The sarcopenia score assessment involves automated selection of the L3 vertebra level slice from abdominal or chest, abdomen, and pelvis (CAP) CT scans, followed by automated segmentation of the muscle area from that slice. Sarcopenia scores were derived from previously established definitions of sarcopenia, with values below 41 cm<sup>2<\/sup>\/m<sup>2<\/sup> for female patients (regardless of BMI) and below 43 cm<sup>2<\/sup>\/m<sup>2<\/sup> or 53 cm<sup>2<\/sup>\/m<sup>2<\/sup> for male (based on BMI &#60; 25 kg\/m<sup>2<\/sup> or &#8805; 25 kg\/m<sup>2<\/sup>). Among the 967 patients with evaluable scans, sarcopenia at baseline was identified in 68.39% (n=329\/481) patients receiving nivolumab (NIVO) with ipilimumab (IPI) and 70.2% (n=341\/486) receiving chemotherapy (Chemo).<br \/>Results: There was a trend of worse overall survival (OS) in patients with baseline sarcopenia across both treatment arms (minimum follow up 49.4 months). In patients with baseline sarcopenia vs ITT, median OS was 16.5 mo vs. 21.8 mo (<i>p=<\/i> 0.219) within the NIVO + IPI arm and 12.9 mo vs.15.0 mo (<i>p=<\/i> 0.273) within the Chemo arm respectively. Any increase in muscle mass from baseline to week 12 was associated with better OS for patients treated with NIVO+IPI (n=98) with sarcopenia at baseline compared to those without an increase in muscle mass (median OS 45.3 mo vs.19.5 mo,<i> p=<\/i> 0.012). This was not seen in those who received Chemo (n=87). Weight and muscle mass were moderately correlated at baseline (r=0.60).<br \/>Conclusions: We found that in CheckMate 227, baseline sarcopenia is associated with numerically worse OS, regardless of treatment, leading to potential use as a negative prognostic biomarker. Patients with NSCLC receiving immunotherapy might benefit from changes in muscle mass being monitored during treatment. Validation of these findings in other studies and other tumor types is warranted.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Nivolumab,Ipilimumab,NSCLC,Prognostic factors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>W. Safta<\/b><sup>1<\/sup>, R. Santana-Davila<sup>2<\/sup>, D. Paulucci<sup>1<\/sup>, W. J. Geese<sup>1<\/sup>, D. J. Grootendorst<sup>1<\/sup>; <br\/><sup>1<\/sup>Bristol Myers Squibb, Princeton, NJ, <sup>2<\/sup>Fred Hutchinson Cancer Center, Seattle, WA","CSlideId":"","ControlKey":"f86c1ca7-9e3e-424b-be27-6974ad7e125b","ControlNumber":"1290","DisclosureBlock":"<b>&nbsp;W. Safta, <\/b> <br><b>BMS<\/b> Employment. <br><b>R. Santana-Davila, <\/b> <br><b>AstraZeneca<\/b> Other, Consulting or advisory role; Research Funding - Institution. <br><b>Mirati Therapeutics<\/b> Other, Consulting or advisory role. <br><b>Genentech\/Roche<\/b> Other, Consulting or advisory role; Research Funding - Institution\u000d\u000a. <br><b>Catalyst Pharmaceuticals<\/b> Other, Consulting or advisory role. <br><b>Amgen<\/b> Other, Consulting or advisory role. <br><b>BeyondSpring Pharmaceuticals<\/b> Other, Research Funding - Institution. <br><b>ISA Pharmaceuticals<\/b> Other, Research Funding - Institution. <br><b>Merck<\/b> Research Funding - Institution. <br><b>Pfizer<\/b> Research Funding - Institution. <br><b>ALX Oncology<\/b> Research Funding - Institution. <br><b>Daiichi Sankyo\/Lilly<\/b> Research Funding - Institution. <br><b>Abbvie<\/b> Research Funding - Institution. <br><b>Astellas Pharma<\/b> Research Funding - Institution. <br><b>Jounce Therapeutics<\/b> Research Funding - Institution. <br><b>Alpine Immune Sciences<\/b> Research Funding - Institution. <br><b>Monte Rosa Therapeutics<\/b> Research Funding - Institution. <br><b>D. Paulucci, <\/b> <br><b>Bristol Myers Squibb<\/b> Employment, Stock. <br><b>W. J. Geese, <\/b> <br><b>Bristol Myers Squibb<\/b> Employment, Stock. <br><b>D. J. Grootendorst, <\/b> <br><b>Bristol Myers Squibb<\/b> Employment, Stock.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2416","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"11","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7650","PresenterBiography":null,"PresenterDisplayName":"Wiem Safta","PresenterKey":"7bc51f80-93a4-41ad-ac11-365b4d4ee473","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7650. An analysis of the prognostic role of sarcopenia derived with fully automated deep learning slice-based muscle estimation in patients with metastatic non-small cell lung cancer (NSCLC)","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"An analysis of the prognostic role of sarcopenia derived with fully automated deep learning slice-based muscle estimation in patients with metastatic non-small cell lung cancer (NSCLC)","Topics":null,"cSlideId":""},{"Abstract":"Chronic lymphocytic leukemia (CLL) is a hematological cancer classified as low-malignancy non-Hodgkin lymphoma that accounts for approximately a quarter of all leukemias. Since only some patients will develop aggressive cancer and require treatment, accurate disease prognosis is crucial. A wide range of parameters with prognostic value have been described, including age, clinical stage, mutational status, protein markers, and flow cytometry levels of CD19+CD38+ B cells above 20%. Here, we investigated epigenetic markers for B cell types including a marker for overall B cells, na&#239;ve B cells, memory B cells and IgM positive B cells in a cohort of more than 40 patients with B-CLL. When comparing to a cohort of more than 100 healthy donors, the epigenetic B cell marker identified all patients with 100% sensitivity and specificity. In addition, the epigenetic B cell markers for na&#239;ve and memory B cells identified with high sensitivity and excellent specificity a subgroup of B-CLL patients with CD19+CD38+ B cell levels above 20% which is associated with an unfavorable prognosis. The results suggest that the epigenetic analysis of B cells in capillary blood may be a promising tool for B-CLL diagnosis and disease prognosis.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Epigenetics,Leukemias: chronic lymphocytic,B cells,Biomarkers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"K. Schildknecht<sup>1<\/sup>, K. Bourquain<sup>1<\/sup>, J. Werner<sup>2<\/sup>, J. Schulze<sup>2<\/sup>, S. Walter<sup>2<\/sup>, E. Raschke<sup>3<\/sup>, D. Phippard<sup>3<\/sup>, <b>A. Bisconte<\/b><sup>3<\/sup>, B. Seliger<sup>4<\/sup>, C. Wickenhauser<sup>4<\/sup>, S. Olek<sup>1<\/sup>; <br\/><sup>1<\/sup>Precision for Medicine, Berlin, Germany, <sup>2<\/sup>Epimune GmbH, Berlin, Germany, <sup>3<\/sup>Precision for Medicine, Frederick, MD, <sup>4<\/sup>Martin Luther University Halle-Wittenberg, Halle\/Saale, Germany","CSlideId":"","ControlKey":"b0ef6908-30e0-48b8-8ee3-6e5d6743932c","ControlNumber":"8479","DisclosureBlock":"<b>&nbsp;K. Schildknecht, <\/b> <br><b>Precision for Medicine<\/b> Employment. <br><b>K. Bourquain, <\/b> <br><b>Precision for Medicine<\/b> Employment. <br><b>J. Werner, <\/b> <br><b>Epimune GmbH<\/b> Employment. <br><b>J. Schulze, <\/b> <br><b>Epimune GmbH<\/b> Employment. <br><b>S. Walter, <\/b> <br><b>Epimune GmbH<\/b> Employment. <br><b>E. Raschke, <\/b> <br><b>Precision for Medicine<\/b> Employment. <br><b>D. Phippard, <\/b> <br><b>Precision for Medicine<\/b> Employment. <br><b>A. Bisconte, <\/b> <br><b>Precision for Medicine<\/b> Employment. <br><b>B. Seliger, <\/b> <br><b>Martin Luther University Halle-Wittenberg<\/b> Employment. <br><b>C. Wickenhauser, <\/b> <br><b>Martin Luther University Halle-Wittenberg<\/b> Employment. <br><b>S. Olek, <\/b> <br><b>Precision for Medicine<\/b> Employment.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2417","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"12","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7651","PresenterBiography":null,"PresenterDisplayName":"Angelina Bisconte, BS","PresenterKey":"741e9ffd-3a05-4601-ae6f-b94ea604deca","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7651. Evaluating epigenetic markers for naive, memory and overall B cells for disease diagnosis and prognosis in patients with B-CLL","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Evaluating epigenetic markers for naive, memory and overall B cells for disease diagnosis and prognosis in patients with B-CLL","Topics":null,"cSlideId":""},{"Abstract":"Background: PC is the third most common malignancy associated with thrombosis, procoagulants may play a role in tumorigenesis and progression, and patients (pts) with PC may have activation of the hemostatic system evident in plasma. The prognostic significance of these markers and their relationship to thrombotic events and overall survival (OS) are under-explored.<br \/>Methods: Patients &#62;18 years were included if they had progressive PC planned to start ADT, were &#62;6 months from surgery or RT, with no history of prior VTE, unexplained bleeding, current or planned anticoagulation, or an additional active malignancy. Plasma samples were obtained via peripheral venipuncture in tubes containing 3.2% sodium citrate and immediately placed on ice. Samples were analyzed for D-dimer, thrombin-antithrombin complex (TAT), IL-6, IL-8, VEGF, and tissue factor (TF) levels by ELISA. Patients had markers drawn at baseline (prior to initiation of ADT), 1 month, and 6 months after initiation.<br \/>Results: 40 patients were accrued with a median age of 68 years. At baseline, 29 (73%) had presence of metastases. Baseline median PSA was 15 and median PSA doubling time was 0.32. Baseline median hemoglobin was 13.85, platelets were 218, D-dimer was 322 ng\/dL, IL-6 was 0 pg\/mL, IL-8 was 0 pg\/mL, TAT was 3 ug\/L, VEGF was 21 pg\/mL, and TF was 26 pg\/mL. Median follow-up was 78 months. During follow up, 35 (87.5%) had metastases. 10 (25%) had thrombotic events (6 [15%] venous, 4 [10%] arterial) at median 37 months follow up. Median baseline age of pts with subsequent thrombotic events was 74, vs 67 in those without a thrombotic event. While there was no significant difference in baseline PSA between groups with and without clotting events, pretreatment PSA doubling time was significantly lower in pts with subsequent thrombosis (0.27 vs 0.35, p=0.047). Median baseline D-dimer and TF were higher in patients with subsequent thrombosis (D-dimer: 516 vs 282, p=0.10; TF: 36 vs 24, p=0.12). In univariate analysis, baseline IL-6 and VEGF were associated with OS (IL-6: HR=1.05, 95% CI [1.01,1.09], p=0.025; VEGF: HR=1.02, 95% CI [1.00,1.03], p=0.028). When controlling for presence of metastasis, baseline TAT was associated with OS (HR=1.05, 95% CI [1.00,1.11], p=0.055).<br \/>Conclusions: Plasma markers of hemostatic activation, fibrinolysis, and angiogenesis prior to initiation of ADT are associated with subsequent thrombotic events and overall survival years later. Further analysis will examine how these markers change over time with hormonal therapy.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Prostate cancer,,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>Jessica  S.  Palmer<\/b><sup><\/sup>, Charlene Thomas<sup><\/sup>, Nicole Jacobs<sup><\/sup>, David Nanus<sup><\/sup>, Scott  T.  Tagawa<sup><\/sup><br><br\/>Weill Cornell Medicine, New York, NY","CSlideId":"","ControlKey":"c5c513a1-0e36-4820-92cd-707be82d9bba","ControlNumber":"5848","DisclosureBlock":"&nbsp;<b>J. S. Palmer, <\/b> None..<br><b>C. Thomas, <\/b> None..<br><b>N. Jacobs, <\/b> None.&nbsp;<br><b>D. Nanus, <\/b> <br><b>Dana-Farber Cancer Institute; Janssen Scientific Affairs<\/b> Other, Advisory\/Scientific Board Member. <br><b>Memorial Sloan Kettering Cancer Center; Telix Pharmaceuticals<\/b> Other, Consultant. <br><b>Aaronson Rappaport Feinstein & Deutsch, LLP; Amabile & Erman, P.C.; Burns White, LLC; Calderhead, Lockemeyer and Peschke Law Office; Danaher Laganes PC; Hinshaw & Culbertson LLP<\/b> Other, Professional Services. <br><b>Kuwait Foundation for the Advancement of Science; Martin, Clearwater & Bell, LLP; McAloon & Friedman, P.C.; Medical College of Wisconsin; O'Brien & Ryan, LLP; Ruprecht Hart Weeks & Ricciardulli, LLP<\/b> Other, Professional Services. <br><b>Shaub, Ahmuty, Citrin & Spratt, LLP; Wadleigh, Starr & Peters, P.L.L.C.; Wicker Smith O'Hara McCoy & Ford, PA<\/b> Other, Professional Services. <br><b>S. T. Tagawa, <\/b> <br><b>Sanofi, Medivation, Astellas, Dendreon, Janssen, Genentech, Bayer, Endocyte, Eisai, Immunomedics, Karyopharm, Abbvie, Tolmar, Seattle Genetics, Amgen, Clovis, QED, Pfizer, AAA\/Novartis, Clarity<\/b> Other, Paid Consultant. <br><b>Genomic Health, POINT Biopharma, Blue Earth, AIkido Pharma, Telix Pharma, Convergent Therapeutics, EMD Serono, Myovant, Merck, Daiichi Sankyo, TransThera, Regeneron, Ambrx<\/b> Other, Paid Consultant. <br><b>Immunomedics\/Gilead\/Weill Cornell<\/b> Patent.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2418","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"13","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7652","PresenterBiography":null,"PresenterDisplayName":"Jessica Palmer, BA;MD","PresenterKey":"6584a2dc-6c80-47dc-a491-b6ba99d42d06","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7652. Plasma markers of hemostasis, fibrinolysis, and angiogenesis prior to androgen deprivation therapy (ADT) in progressive prostate cancer (PC) and associations with long-term thrombotic events and survival","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Plasma markers of hemostasis, fibrinolysis, and angiogenesis prior to androgen deprivation therapy (ADT) in progressive prostate cancer (PC) and associations with long-term thrombotic events and survival","Topics":null,"cSlideId":""},{"Abstract":"Purpose: Luminal-type breast cancers are the most commonly diagnosed in women. Among them, the luminal B1 subtype exhibits higher proliferation rates and a worse prognosis compared to the luminal A subtype. Despite significant advancements in detection and therapies, recurrence still occurs after primary treatment. In this study, our aim is to identify genomic alterations in early recurrent luminal B1 breast cancer.<br \/>Experimental Design: In this VGHTPE cohort, we recruited a total of 42 patients diagnosed with stage I-III luminal B1 breast cancer, comprising 15 subjects who experienced recurrence within five years and 27 subjects who did not. Genomic DNA was extracted from formalin-fixed paraffin-embedded samples and subjected to targeted next-generation sequencing. We assessed cell aggressiveness through in vitro transwell migration, invasion, and sphere assays.<br \/>Results: Luminal B1 breast cancer patients with advanced stage and poorly differentiated tumors were associated with recurrence within five years. Driver gene mutation analysis revealed that <i>TP53 <\/i>mutations were present in 46.7% of patients who experienced recurrence within five years, compared to 29.6% in the non-recurrence group. In the analysis of copy number variations, the most common amplifications\/gains observed in luminal B1 breast cancer patients were in <i>MCL1<\/i>, <i>MYC<\/i>, and <i>KLF6<\/i>. Remarkably, patients who experienced recurrence within five years showed a higher occurrence of gain in <i>ITGB2<\/i>, the gene encoding the integrin &#946; chain, compared to those who remained recurrence-free. Patients with <i>ITGB2 <\/i>amplifications\/gains had a shorter 5-year recurrence-free survival compared to those with a neutral status. <i>In vitro<\/i> studies revealed that the knockdown of ITGB2 suppressed cell migration, invasion, and sphere formation in estrogen receptor-positive HER2-negative breast cancer cells.<br \/>Conclusion: Our study has identified <i>ITGB2 <\/i>amplifications\/gains as a potential biomarker for early recurrence in luminal B1 breast cancer.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Breast cancer,Recurrence,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>C.-Y. Liu<\/b>, J.-L. Chen, Y.-F. Tsai, T.-C. Chao, W.-L. Wang, P.-J. Lien, C.-Y. Hsu, J.-I. Lai, C.-C. Huang, J.-H. Chiu, L.-M. Tseng; <br\/>Taipei Veterans General Hospital, Taipei, Taiwan","CSlideId":"","ControlKey":"c82ca5db-ae31-4936-aa9d-7163b8b5e7f9","ControlNumber":"539","DisclosureBlock":"&nbsp;<b>C. Liu, <\/b> None..<br><b>J. Chen, <\/b> None..<br><b>Y. Tsai, <\/b> None..<br><b>T. Chao, <\/b> None..<br><b>W. Wang, <\/b> None..<br><b>P. Lien, <\/b> None..<br><b>C. Hsu, <\/b> None..<br><b>J. Lai, <\/b> None..<br><b>C. Huang, <\/b> None..<br><b>J. Chiu, <\/b> None..<br><b>L. Tseng, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2419","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"14","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7653","PresenterBiography":null,"PresenterDisplayName":"Chun-Yu Liu, PhD","PresenterKey":"9b2d0d18-c333-4f07-a760-690a6d70340e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7653. Role of ITGB2 in patients with luminal B1 breast cancer","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Role of ITGB2 in patients with luminal B1 breast cancer","Topics":null,"cSlideId":""},{"Abstract":"Introduction: Tertiary lymphoid structure (TLS) has been found to associate with good prognosis in various cancer types including esophageal squamous cell carcinoma (ESCC). A recent study involving patients receiving curative surgical resection alone for localized ESCC showed TLS as a favorable prognostic factor associated with improved progression free survival (Hayashi et al. British Journal of Cancer, 2023;128:2175-2185). Our study aimed to investigate the prognostic significance of TLS in patients with locally advanced ESCC receiving neoadjuvant chemoradiotherapy (CRT).<br \/>Patients and Methods: We retrospectively enrolled 137 patients of locally advanced ESCC patients from two referral centers of Taiwan from 2002 to 2018. All patients received paclitaxel\/platinum-based CRT followed by esophagectomy. Primary esophageal tumor tissues biopsied endoscopically before treatment were collected for immunohistochemical stains for CD20 (clone L26; Zytomed, Berlin, Germany) and CD23 (clone DAK-CD23; agilent Dako, California, U.S.A.). The TLS status of each patient was defined as no TLS (no aggregation of CD20-positive cells), immature TLS (aggregation of CD20-positive cells without CD23-positive cells in it), and mature TLS (aggregation of CD20-positive cells with CD23-positive cells in it). The associations of the TLS status with pathologic complete response (pCR) and overall survival (OS) were analyzed univariately and multivariately by logistic regression and cox regression, respectively. The variables included in the analyses were age, gender, tumor location, clinical T stage, clinical N stage, the institutes, PD-L1 expression on tumor cells (PD-L1 TC) and immune cells (PD-L1 IC), and the TLS status.<br \/>Results: The median age was 54 years with 125 males and 12 females. The TLS status of no, immature, and mature TLS were seen in 64, 40, and 33 patients, respectively. Mature TLS was associated with PD-L1 IC (p=0.0007). Compared to no TLS, mature TLS associated with lower pCR rate (24% vs 47%) in both univariate (OR: 0.36, p=0.034) and multivariate (OR: 0.26, p=0.023) analysis. Compared to no TLS, mature TLS was associated with shorter OS (median OS: 27 vs 46 months) in multivariate analysis (HR: 2.96, p=0.0008), but not in univariate analysis (HR: 1.29, p=0.29). Other prognostic factors associated with OS in multivariate analysis include male gender (HR: 2.88, p=0.021), PD-L1 TC (HR: 1.62, p=0.039), and PD-L1 IC (HR: 0.30, p&#60;0.0001).<br \/>Conclusion: Mature TLS is an independent factor for poor treatment outcomes, including pathologic response and overall survival in locally advanced ESCC patients receiving neoadjuvant CRT. Additional studies are warranted to validate this finding. (The study was supported by the grant NTUH 110-S5021, MOST 108-2314-B-002-076-MY3, and MOHW 111-TDU-B-221-114006)","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Prognostic factors,Tertiary lymphoid structure,neoadjuvant Chemoradiotherapy,esophageal squamous cell carcinoma,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>T.-C. Huang<\/b><sup>1<\/sup>, C.-W. Liang<sup>2<\/sup>, Y.-I. Li<sup>2<\/sup>, J.-C. Guo<sup>3<\/sup>, C.-C. Lin<sup>1<\/sup>, J.-M. Lee<sup>1<\/sup>, Y.-K. Chao<sup>4<\/sup>, C.-H. Hsu<sup>1<\/sup>; <br\/><sup>1<\/sup>National Taiwan University Hospital, Taipei, Taiwan, <sup>2<\/sup>Fu-Jen Catholic University Hospital, New Taipei City, Taiwan, <sup>3<\/sup>National Taiwan University Cancer Center, Taipei, Taiwan, <sup>4<\/sup>Chang-Gung Memorial Hospital, LinKou, Taoyuamg, Taiwan","CSlideId":"","ControlKey":"470e6aea-99e4-4349-99e3-7322f291949d","ControlNumber":"4313","DisclosureBlock":"&nbsp;<b>T. Huang, <\/b> None..<br><b>C. Liang, <\/b> None..<br><b>Y. Li, <\/b> None..<br><b>J. Guo, <\/b> None..<br><b>C. Lin, <\/b> None..<br><b>J. Lee, <\/b> None..<br><b>Y. Chao, <\/b> None..<br><b>C. Hsu, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2420","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"15","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7654","PresenterBiography":null,"PresenterDisplayName":"Ta-Chen Huang, MD","PresenterKey":"86e95685-71e1-47d4-beec-3aa3174f3025","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7654. Tertiary lymphoid structure associates with poor prognosis in locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Tertiary lymphoid structure associates with poor prognosis in locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy","Topics":null,"cSlideId":""},{"Abstract":"<b>Purpose: <\/b>High-grade glioma (HGG), the most common form of primary brain tumor, is highly lethal and treatment options remain limited. Despite advances in genomic technologies, there are few molecular biomarkers to guide precision medicine for HGG. Here, we aimed to identify the clinicogenomic features associated with HGG prognosis and recurrence patterns.<br \/><b>Methods: <\/b>Our single-institution retrospective analysis included 220 patients initially diagnosed with adult HGG (grade 3 or 4) who underwent next-generation sequencing targeting 82 brain tumor-relevant genes. The patients were categorized according to the 2021 WHO classification and their clinical status, survival, genomic profile, and recurrence patterns were analyzed.<br \/><b>Results:<\/b> At a median follow-up of 23 months (ranges, 2-59 months), 180 patients (82%) showed either progression or recurrence. A total of 15% of patients were reclassified under the 2021 WHO classification, revealing a clear separation of progression-free survival (PFS) and overall survival (OS) curves between grades 3 and 4 gliomas. We found that <i>TP53<\/i> mutations were significantly associated with the occurrence of distant progression, especially in grade 4 gliomas. Additionally, <i>TP53<\/i> mutations were more common in patients with higher Ki67 index and subependymal\/leptomeningeal seeding, indicating an increased risk of distant progression in <i>TP53<\/i>-mutated grade 4 glioma patients. Following multivariate Cox regression analysis,<i> TP53 <\/i>mutations were independent predictors of OS (hazard ratio [HR]=1.47, P=0.039) and distant PFS (HR=1.71, P=0.005).<br \/><b>Conclusion: <\/b>Considering the elevated risk of distant progression in grade 4 gliomas with TP53 mutations, our results underscore the necessity for additional research into the most effective treatment approaches for these patients.<br \/><b> <\/b> <b>Keywords: <\/b>high-grade glioma, <i>TP53<\/i>, pattern of failure, distant progression, next-generation sequencing","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Glioma,TP53,Distant progression,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>B.-H. Kang<\/b><sup>1<\/sup>, S. Lee<sup>2<\/sup>, J. Lee<sup>2<\/sup>; <br\/><sup>1<\/sup>Ewha Womans University School of Medicine, Seoul, Korea, Republic of, <sup>2<\/sup>Seoul National University College of Medicine, Seoul, Korea, Republic of","CSlideId":"","ControlKey":"c9631ee7-8c6e-4a37-a444-93330fe8d975","ControlNumber":"6178","DisclosureBlock":"&nbsp;<b>B. Kang, <\/b> None..<br><b>S. Lee, <\/b> None..<br><b>J. Lee, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2422","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"16","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7656","PresenterBiography":null,"PresenterDisplayName":"Byung-Hee Kang","PresenterKey":"cdb438cd-46ef-444e-9762-c3dde91cd7ca","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7656. Clinicogenomic anlaysis reveals a role for TP53 mutations in distant progression of high-grade glioma","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Clinicogenomic anlaysis reveals a role for TP53 mutations in distant progression of high-grade glioma","Topics":null,"cSlideId":""},{"Abstract":"Introduction: <i>KMT2A (MLL) <\/i>rearrangements (fusions) is a therapeutic biomarker for Menin inhibitors. <i>KMT2A<\/i>-PTDs (partial tandem duplications) are considered a prognostic biomarker in myeloid malignancies. <i>KMT2A<\/i> fusions and PTDs are traditionally detected by RT-qPCR (quantitative real-time PCR). This study investigates <i>KMT2A<\/i> PTDs levels in healthy donors and myeloid malignancy samples to establish a threshold to report samples with high PTDs, using next generation sequencing (NGS) with Oncomine<sup>TM<\/sup><sup> <\/sup>Myeloid Assay GX v2. We also report <i>KMT2A<\/i> fusions in myeloid malignancies.<br \/>Methods: We sequenced 8483 research samples with known myeloid malignancies at Sonora Quest Laboratories<sup>TM<\/sup> and at Thermo Fisher Scientific<sup>TM<\/sup>. We acquired 20 healthy donor whole blood samples (total 127 replicates) from Stanford<sup>TM<\/sup> Blood Center and Discovery Life Sciences<sup>TM<\/sup> and sequenced them at 3 different sites of Thermo Fisher Scientific<sup>TM<\/sup>. Samples were sequenced with the Ion Torrent<sup>TM<\/sup><sup> <\/sup>Genexus<sup>TM<\/sup> 6.6 or Ion GeneStudio<sup>TM<\/sup><sup> <\/sup> S5 System. They were profiled for 6 different <i>KMT2A<\/i>-PTD variants and 199 <i>KMT2A<\/i> fusion isoforms.<br \/>Results: The mean read length of this data set is 90 - 120 bp and the mean mapped fusion reads is 20,000 - 30,000. <i>KMT2A<\/i>-PTDs were detected in both healthy donors and myeloid samples. Healthy donor PTD read counts were consistently &#60;2000 and averaged 1\/3 of myeloid sample PTD read counts. About 33% of myeloid samples had higher PTD read counts than any healthy donor sample. BLAT (BLAST-Like Alignment Tool) analysis confirmed specific exon matching on the <i>KMT2A<\/i> gene in both cohorts. Among the 8483 myeloid samples, 162 samples contained a total of 5 unique <i>KMT2A<\/i> PTDs, and 105 samples contained a total of 30 unique <i>KMT2A<\/i> fusion isoforms with <i>KMT2A<\/i>-<i>MLLT1<\/i> and <i>KMT2A<\/i>-<i>MLLT3<\/i> being the most prevalent <i>KMT2A<\/i> fusion gene pairs.<br \/>Conclusions: We characterize the <i>KMT2A<\/i> fusions present in myeloid malignant samples. We also describe the abundance of <i>KMT2A<\/i> PTDs in both healthy donor and myeloid samples, with myeloid cases showing significantly higher PTD read counts. <i>KMT2A<\/i> PTD read count &#62;2000 is present only in malignant samples but not in healthy donors. This intriguing finding opens opportunities for prospective studies to monitor individuals with elevated PTD levels for myeloid malignancy development and retrospective studies to explore whether healthy donors identified with this alteration years ago after blood donation were subsequently recorded in the national health system with myeloid malignancies.<br \/>(For research use only. Not for use in diagnostic procedures. &#169; 2023 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. Stanford is a trademark of the Board of Trustees of the Leland Stanford Junior University. Discovery Life Sciences is a trademark of Discovery Life Sciences. Sonora Quest Laboratories is a trademark of Sonora Quest Laboratories.)","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Acute myeloid leukemia,Next-generation sequencing (NGS),Molecular diagnosis,Fusion genes,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>J. Huang<\/b><sup>1<\/sup>, H. Gu<sup>2<\/sup>, J. Orton<sup>2<\/sup>, M. Sedova<sup>1<\/sup>, A. Marcovitz<sup>1<\/sup>, J. Burke<sup>1<\/sup>, S. Brozio<sup>1<\/sup>, P. Williams<sup>3<\/sup>, S. Myrand<sup>3<\/sup>, N. Olowo<sup>1<\/sup>, A. Broomer<sup>4<\/sup>, B. Deal<sup>1<\/sup>, C. Seeger<sup>5<\/sup>, S. Sadis<sup>3<\/sup>, S. Rozenzhak<sup>4<\/sup>, F. Hyland<sup>1<\/sup>, G. Liu<sup>2<\/sup>; <br\/><sup>1<\/sup>Thermo Fisher Scientific, South San Francisco, CA, <sup>2<\/sup>Sonora Quest Laboratories, Phoenix, AZ, <sup>3<\/sup>Thermo Fisher Scientific, Ann Arbor, MI, <sup>4<\/sup>Thermo Fisher Scientific, Carlsbad, CA, <sup>5<\/sup>Thermo Fisher Scientific, Guilford, CT","CSlideId":"","ControlKey":"cb8b7c31-0199-4332-8fcf-93c893121659","ControlNumber":"1495","DisclosureBlock":"&nbsp;<b>J. Huang, <\/b> None..<br><b>H. Gu, <\/b> None..<br><b>J. Orton, <\/b> None..<br><b>M. Sedova, <\/b> None..<br><b>A. Marcovitz, <\/b> None..<br><b>J. Burke, <\/b> None..<br><b>S. Brozio, <\/b> None..<br><b>P. Williams, <\/b> None..<br><b>S. Myrand, <\/b> None..<br><b>N. Olowo, <\/b> None..<br><b>A. Broomer, <\/b> None..<br><b>B. Deal, <\/b> None..<br><b>C. Seeger, <\/b> None..<br><b>S. Sadis, <\/b> None..<br><b>S. Rozenzhak, <\/b> None..<br><b>F. Hyland, <\/b> None..<br><b>G. Liu, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2423","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"17","PosterboardNumber":"18","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7657","PresenterBiography":null,"PresenterDisplayName":"Jiajie Huang, PhD","PresenterKey":"f1e4129c-23dd-48ce-a0cd-67f59ab0a393","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7657. Detection of <i>KMT2A<\/i>-PTDs and <i>KMT2A<\/i> fusions using next generation sequencing","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Detection of <i>KMT2A<\/i>-PTDs and <i>KMT2A<\/i> fusions using next generation sequencing","Topics":null,"cSlideId":""},{"Abstract":"<b>Background:<\/b> Programmed cell death ligand 1 (PD-L1) expression alone has limited predictive value for pembrolizumab plus 5-fluorouracil and platinum (PFP) therapy in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). An artificial intelligence (AI)-powered spatial tumor-infiltrating lymphocyte (TIL) analyzer may provide independent prognostic information.<br \/><b>Methods:<\/b> This study included 63 patients with locally incurable HNSCC who received first-line PFP at Samsung Medical Center. Patients were classified into inflamed phenotype (IP) or non-inflamed phenotype (NIP) based on the 5% proportion threshold of inflamed 1 mm<sup>2<\/sup>-sized grids over total grids within hematoxylin and eosin-stained whole-slide images (WSIs) analyzed using Lunit SCOPE IO. We evaluated the prognostic value of inflamed status and densities of intratumoral TILs (iTILs), stromal TILs (sTILs), and tumor microenvironment TILs (tTILs).<br \/><b>Results:<\/b> Patients were predominantly male (78%). The median age at PFP initiation was 57 years. The most common primary tumor site was oral cavity (49.2%), followed by oropharynx (16%) and hypopharynx (10%). Of the 37 patients with available PD-L1 combined positive score (CPS), 2 (5%), 23 (62%), and 12 (32%) had CPS values of &#60;1, 1-19, and &#8805;20, respectively. The overall response rate was 54%, with 67% in the CPS &#8805;20 subgroup and 48% in the CPS &#60;20 subgroup. The median progression-free survival (PFS) was 7.2 months, with 10.8 months for patients with CPS &#8805;20 and 5.5 months for patients with CPS &#60;20. The median overall survival (OS) was 18.6 months. Among 62 patients with available WSIs, 47 (74%) and 15 (26%) patients were categorized as having an IP and NIP, respectively. Oral cavity cancer was enriched with IP (57.4% of all IP cases vs 26.7% of all NIP cases), while all four paranasal sinus tumors had NIP. The overall response rate was 57% in the IP group and 44% in the NIP group. Patients with IP had significantly longer PFS and OS than patients with NIP, both in unadjusted (hazard ratio<br \/>[HR] for PFS, 0.4; 95% confidence interval [CI], 0.21-0.78; P = 0.007; HR for OS, 0.43; 95% CI, 0.2-0.95; P = 0.036) and PD-L1 CPS-adjusted analyses (HR for PFS, 0.41; 95% CI, 0.21-0.79; P = 0.008; HR for OS, 0.4; 95% CI, 0.18-0.89; P = 0.025). High densities (&#8805;25th percentile) of iTILs, sTILs, and tTILs were all significantly associated with prolonged PFS after CPS adjustment (P = 0.001, 0.001, and 0.012). High density of iTILs was also significantly associated with improved OS (P = 0.001 after CPS adjustment), while there was no significant association between OS and high density of sTILs or tTILs (0.077 and 0.085, respectively, after CPS adjustment).<br \/><b>Conclusion: <\/b>An<b> <\/b>AI-driven spatial TIL analyzer might serve as a simple and independent prognostic biomarker in HNSCC patients receiving pembrolizumab plus chemotherapy.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Tumor infiltrating lymphocytes,Artificial intelligence,PD-L1,Pembrolizumab,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>S. Park<\/b><sup>1<\/sup>, J. Shin<sup>1<\/sup>, C.-Y. Ock<sup>2<\/sup>, C. Ahn<sup>2<\/sup>, H. Jung<sup>1<\/sup>, S.-H. Lee<sup>1<\/sup>, M.-J. Ahn<sup>1<\/sup>; <br\/><sup>1<\/sup>Samsung Medical Center, Seoul, Korea, Republic of, <sup>2<\/sup>Lunit, Seoul, Korea, Republic of","CSlideId":"","ControlKey":"d1d7af75-4ff5-4477-bc39-a304bfcfe39c","ControlNumber":"5996","DisclosureBlock":"&nbsp;<b>S. Park, <\/b> None..<br><b>J. Shin, <\/b> None.&nbsp;<br><b>C. Ock, <\/b> <br><b>Lunit<\/b> Employment. <br><b>C. Ahn, <\/b> <br><b>Lunit<\/b> Employment.<br><b>H. Jung, <\/b> None..<br><b>S. Lee, <\/b> None..<br><b>M. Ahn, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2424","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"18","PosterboardNumber":"19","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7658","PresenterBiography":null,"PresenterDisplayName":"Sehhoon Park, MD","PresenterKey":"0fb7628f-d026-44e0-a06a-351dbb42fbeb","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7658. Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a prognostic biomarker for pembrolizumab plus chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a prognostic biomarker for pembrolizumab plus chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma","Topics":null,"cSlideId":""},{"Abstract":"The pivotal role of biomarkers in personalizing patient treatment and guiding drug development is well-recognized, with the ultimate goal of enhancing therapeutic efficacy and patient quality of life by minimizing adverse events. Their development, however, is challenged by strict regulations and high costs, leading to sparse and varied data collected over extended periods and through diverse technologies. These variations complicate the harmonization and analysis of the data. Traditional methods struggle to navigate these complexities, further obscuring biomarker identification. For instance, PDL-1, approved as a biomarker by the FDA, has its effectiveness debated in several studies. To address these issues, we introduce Biomarkers Navigator, a flexible and automated analysis framework engineered explicitly for the robust identification of biomarkers. This framework is designed to aggregate, standardize, and store expansive biomarker information, ensuring efficient and traceable knowledge retrieval. By pre-calculating each potential biomarker, Biomarkers Navigator enables immediate and comprehensive meta-analyses, facilitating rapid decision-making tailored to the level of risk acceptance. Large Language Models (LLMs) further enhance the framework's capability to uncover signatures of response and resistance. LLM integration has accelerated the discovery of new potential biomarkers for hematological malignancies by combining prior knowledge and previously obscured associations. Our approach demonstrates the feasibility of large-scale hypothesis-free analysis and substantiates the utility of AI in unveiling hidden biological connections within clinical data. Our findings underscore the potential of AI-augmented frameworks in revolutionizing biomarker discovery and advancing personalized medicine.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Biomarkers,Bioinformatics,Databases,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>I. Kagiampakis<\/b><sup>1<\/sup>, M. Gidwani<sup>2<\/sup>, I. Korkodinov<sup>2<\/sup>, G. Ponomarev<sup>2<\/sup>, E. Jacob<sup>3<\/sup>; <br\/><sup>1<\/sup>AstraZeneca US, San Francisco, CA, <sup>2<\/sup>AstraZeneca US, Gaithersburg, MD, <sup>3<\/sup>AstraZeneca US, Waltham, MA","CSlideId":"","ControlKey":"4280eaf2-59b6-4e5f-87f7-a629d9ccfff8","ControlNumber":"7064","DisclosureBlock":"<b>&nbsp;I. Kagiampakis, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>M. Gidwani, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>I. Korkodinov, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>G. Ponomarev, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>E. Jacob, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2425","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"19","PosterboardNumber":"20","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7659","PresenterBiography":null,"PresenterDisplayName":"Ioannis Kagiampakis, MS;PhD","PresenterKey":"ae26dfb7-a514-462e-a794-fab2ddd3c2c7","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7659. AI-driven hypothesis-free analysis for biomarker discovery: Introducing the Biomarkers Navigator Framework","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"AI-driven hypothesis-free analysis for biomarker discovery: Introducing the Biomarkers Navigator Framework","Topics":null,"cSlideId":""},{"Abstract":"Availability of the semi-essential amino acid L-arginine (L-arg) is limiting for proliferation in highly proliferative tissues. L-Arg is also a substrate for nitric oxide synthases (NOS) and arginases (ARG) 1 and 2. Methylation of L-arg residues within proteins by protein L-arg methyltransferases (PRMTs) leads to asymmetric (ADMA) and symmetric dimethylarginine (SDMA). Protein L-arg methylation is an important post-translational mechanism to regulate gene expression and cell cycle control. We measured L-arg and its metabolites in a prospective cohort of patients with primary breast cancer (BC). We further measured these metabolites and expression of genes involved in L-arg metabolic pathways in cell lines representing intrinsic BC subtypes. Plasma L-arg-related metabolite concentrations from 243 women with primary BC were associated with total mortality and disease recurrence during a median follow-up of 88 (IQR, 82-93) months. MCF-7, BT-474, SK-BR-3, and MDA-MB-468 cells representing ER-positive, HER2-positive, and triple negative BC were cultured in standard conditions and compared to MCF-12A normal breast epithelial cells. The plasma (<i>in vivo<\/i>) and intracellular concentrations (<i>in vitro<\/i>) of L-arg, L-ornithine (L-orn), L-citrulline (L-cit), ADMA, and SDMA were measured by UPLC-MS\/MS. mRNA expression was quantified by qRT-PCR and protein expression was analyzed by Western Blot. In vivo, the plasma concentrations of all L-arg metabolites differed significantly between BC patients and healthy controls. L-Arg and ADMA were significantly higher in patients with recurrent disease and in those who died during follow up. ADMA was significantly associated with total mortality and recurrent disease in Luminal A patients; low L-orn\/L-arg ratio was associated with survival in HER2+ BC patients, and low L-cit was associated with survival in triple negative BC. With the exception of MCF-7 cells, DDAH1 and DDAH2 mRNA concentrations in vitro were significantly higher in BC cells than in MCF-12A cells (DDAH1: 32-44 fold, DDAH2: 1.7-4.2 fold; p&#60;0.05). These differences were mirrored by DDAH1 and DDAH2 protein concentrations. By contrast, MCF-7 cells were characterized by low DDAH1 and DDAH2, but high PRMT4 and PRMT6 mRNA expression and high L-arg content. BT-474 cells showed high ARG2 expression and high L-arg and L-orn concentrations, and MDA-MB-468 cells had the highest L&#8209;cit\/L-arg ratio. In conclusion, regulation of L-arg metabolic pathways shows a complex and differential pattern between intrinsic BC subtypes, which is mirrored in representative cell lines in vitro. ADMA is a prognostic biomarker in Luminal A breast cancer patients; its metabolizing enzyme, DDAH, is highly overexpressed in BC cells in vitro. Thus, fingerprinting of L-arg metabolism may offer novel personalized treatment options within intrinsic BC subtypes.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Breast cancer,Survival,Biomarkers,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>J. Hannemann<\/b><sup>1<\/sup>, L. Oliveira Ferrer<sup>1<\/sup>, A. R√∂glin<sup>1<\/sup>, F. Kleinsang<sup>1<\/sup>, V. M√ºller<sup>1<\/sup>, I. Witzel<sup>2<\/sup>, R. B√∂ger<sup>1<\/sup>; <br\/><sup>1<\/sup>University Medical Center Hamburg-Eppendorf, Hamburg, Germany, <sup>2<\/sup>University Hospital Z√ºrich, Z√ºrich, Switzerland","CSlideId":"","ControlKey":"667ad3bf-4f54-42b2-8a35-a906181c09a7","ControlNumber":"1878","DisclosureBlock":"&nbsp;<b>J. Hannemann, <\/b> None..<br><b>L. Oliveira Ferrer, <\/b> None..<br><b>A. R√∂glin, <\/b> None..<br><b>F. Kleinsang, <\/b> None..<br><b>V. M√ºller, <\/b> None..<br><b>I. Witzel, <\/b> None..<br><b>R. B√∂ger, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2426","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"20","PosterboardNumber":"21","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7660","PresenterBiography":null,"PresenterDisplayName":"Juliane Hannemann, PhD","PresenterKey":"15510203-c643-4980-9d07-acc688232c1f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7660. L-Arginine metabolism is of prognostic relevance in women with breast cancer, but varies considerably between subtypes in vitro - A bedside-to-bench translational approach","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"L-Arginine metabolism is of prognostic relevance in women with breast cancer, but varies considerably between subtypes in vitro - A bedside-to-bench translational approach","Topics":null,"cSlideId":""},{"Abstract":"<b>Background<\/b>: HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) is a unique disease with improved prognosis which could benefit from treatment de-escalation. Current radiographic-based biomarkers mainly focus on primary tumor (PT) alone, neglecting the potential prognostic value from the lymph node (LN). In this work, we constructed a radiomic model integrating texture features from both PT and LN to predict overall survival (OS) in HPV-associated OPSCC patients.<br \/><b>Methods: <\/b>Pretreatment CT scans for 647 OPSCC patients treated with definitive radiation with or without chemotherapy were acquired from The Cancer Imaging Archive (TCIA) and the Cleveland Clinic (CCF), which were divided into training set D<sub>1<\/sub> (n=294) and test set D<sub>2<\/sub> (n=353). PT and LN contours were annotated by three. 2045 texture radiomic features were extracted from both PT and LN and were concatenated as input to a LASSO Cox model to predict OS. We used the harrell&#8217;s concordance index (C-index) and hazard ratio (HR) to evaluate the prognostic performance. We also performed the multivariable cox proportional hazard analysis adjusting for clinicopathological variables to validate the independent prognostic significance.<br \/><b>Results: <\/b>Among the 647 patients, median follow-up time was 70.23 months, with 155 patients (24%) experienced death. 22.6%, 38.8%, 23.2% and 15.4% had T stage I, II, III and IV tumors, respectively. 203 patients (31.4%) were treated with radiation alone. The model integrating PT and LN (M_PTLN) yielded higher C-index compared to PT alone (M_PT) on D1 (0.74 vs 0.66) and on D2 (0.64 vs 0.61). In univariate analysis on D2, M_PTLN is prognostic of OS (HR, 2.26; 95% CI, 1.32 - 3.87; log rank p = 0.003). In multivariable analysis, M_PTLN is still statistically significant (p = 0.04) accounting for clinicopathologic factors (age, gender, smoking pack-year [PY], T stage, N stage and treatment modality).<br \/><b>Conclusions: <\/b>We developed and validated a CT-based survival prediction model for HPV-associated OPSCC patients with significant prognostic values, accounting for both primary tumor and lymph node. If prospectively validated, the model has the potential to inform trial eligibility and treatment-related decision making.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Prognostic markers,Machine learning,Image analysis,Survival,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>B. Song<\/b><sup>1<\/sup>, A. Leroy<sup>2<\/sup>, K. Yang<sup>3<\/sup>, Q. Liu<sup>4<\/sup>, X. Li<sup>1<\/sup>, J. Lee<sup>3<\/sup>, S. Stock<sup>3<\/sup>, N. F. Saba<sup>1<\/sup>, J. S. Lewis, Jr.<sup>5<\/sup>, E. Deutsch<sup>6<\/sup>, M. Bilen<sup>7<\/sup>, S. A. Koyfman<sup>3<\/sup>, A. Madabhushi<sup>1<\/sup>; <br\/><sup>1<\/sup>Emory University, Atlanta, GA, <sup>2<\/sup>therapanacea, Paris, France, <sup>3<\/sup>Cleveland Clinic, Cleveland, OH, <sup>4<\/sup>California State University, Los Angeles, CA, <sup>5<\/sup>Vanderbilt University Medical Center, Nashville, TN, <sup>6<\/sup>Paris-Saclay University, Paris, France, <sup>7<\/sup>Winship Cancer Institute, Atlanta, GA","CSlideId":"","ControlKey":"f2083e77-74e5-4114-901d-ae0cff00d5de","ControlNumber":"7208","DisclosureBlock":"&nbsp;<b>B. Song, <\/b> None.&nbsp;<br><b>A. Leroy, <\/b> <br><b>a.leroy@therapanacea.eu<\/b> Employment.<br><b>K. Yang, <\/b> None..<br><b>Q. Liu, <\/b> None..<br><b>X. Li, <\/b> None..<br><b>J. Lee, <\/b> None..<br><b>S. Stock, <\/b> None..<br><b>N. F. Saba, <\/b> None..<br><b>J. S. Lewis, <\/b> None.&nbsp;<br><b>E. Deutsch, <\/b> <br><b>GRAEGIS<\/b> Employment.<br><b>M. Bilen, <\/b> None..<br><b>S. A. Koyfman, <\/b> None.&nbsp;<br><b>A. Madabhushi, <\/b> <br><b>Picture Health<\/b> Employment. <br><b>Elucid Bioimaging<\/b> Employment. <br><b>Inspirata Inc<\/b> Employment. <br><b>Aiforia Inc<\/b> Employment. <br><b>SimBioSys<\/b> Employment.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2427","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"21","PosterboardNumber":"22","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7661","PresenterBiography":null,"PresenterDisplayName":"Bolin Song","PresenterKey":"7aa3f38e-d0a1-4d5c-ac37-71c9ec35cfdd","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7661. Integrating radiomic features from primary tumor and lymph node for survival prediction of HPV-associated oropharyngeal squamous cell carcinoma","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Integrating radiomic features from primary tumor and lymph node for survival prediction of HPV-associated oropharyngeal squamous cell carcinoma","Topics":null,"cSlideId":""},{"Abstract":"Ovarian cancer is the deadliest among gynecologic cancers. It is partly due to the mild symptoms in early stages and relatively high diagnostic age (about 63-year-old median age). These factors contribute to the short chemotherapy response time and survival time with about 18- and 36-months median progression-free survival and overall survival duration, respectively. The advancements of convolutional neural network (CNN) machine learning algorithms provide opportunities for the development of cost- and time-effective models which is urgently needed for ovarian cancer patients, especially for those with elevated risk. A CNN model was trained with hematoxylin and eosin (H&#38;E) stained tumor whole slide images (WSIs) from ovarian cancer patients with advanced stages. 773 WSIs of 335 patients from TCGA-OV dataset were separated randomly for training and testing cohort. The model was then applied on testing cohort with advanced stage and age patients for H&#38;E survival score. The c-index of the predicted risk on overall survival (OS) and progression-free survival (PFS) were 0.66 and 0.63, respectively. The log-rank p-values of patients between low and high risk were 0.00137 and 0.00138, respectively. The model was then further evaluated with an external dataset. The c-index of the predicted risk were 0.64 and 0.72 for OS and PFS, respectively. And the log-rank test between patients with low and high risk achieved p-values 0.017 and 0.0047 for OS and PFS, respectively. In conclusion, a novel prognostic CNN model was developed for ovarian cancer patients with advanced age and stage for better disease management.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Ovarian cancer,Prognostic markers,Deep learning,Image analysis,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>C. Ng<\/b>, K.-k. Wong, B. Lawson, S. Ferri-Borgogno, S. Mok; <br\/>UT MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"71c02e03-91aa-4048-a77b-d94a916f4fe2","ControlNumber":"1955","DisclosureBlock":"&nbsp;<b>C. Ng, <\/b> None..<br><b>K. Wong, <\/b> None..<br><b>B. Lawson, <\/b> None..<br><b>S. Ferri-Borgogno, <\/b> None..<br><b>S. Mok, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2428","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"22","PosterboardNumber":"23","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7662","PresenterBiography":null,"PresenterDisplayName":"Chun Wai (Oscar) Ng, PhD,MS","PresenterKey":"03fc7956-e320-48e4-8eb8-0dbfee742e2f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7662. Convolutional neural network algorithms and hematoxylin-and-eosin-stained images predict clinical outcomes in high-grade serous ovarian cancer patients with advanced age and stage","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Convolutional neural network algorithms and hematoxylin-and-eosin-stained images predict clinical outcomes in high-grade serous ovarian cancer patients with advanced age and stage","Topics":null,"cSlideId":""},{"Abstract":"Introduction: Multiple myeloma (MM) is a heterogeneous disease with a small subset of high-risk patients associated with poor prognosis. The identification of these patients is crucial for treatment management and strategic decisions.<br \/>Methods: We developed a novel computational framework that only requires gene expression profiles to define prognostic gene signatures by selecting genes with expression driven by inferred clonal copy number alterations. We applied this framework to MM and developed a clonal gene signature (CGS) consisting of only 22 genes. This prognostic signature was evaluated in 5 independent datasets with gene expression data of a total of 2,155 MM samples. For each patient, we calculated a prognostic score based on the expression of the signature genes. Multivariate Cox regression analyses were performed to investigate the association of these signature scores with patient prognosis after adjusting established clinical factors. The performances of CGS and the only commercialized MM gene signatures, GEP70 and SKY92, in identifying high-risk patients were carefully compared by multiple different approaches.<br \/>Results: Our results indicated that CGS provided significant prognostic values after adjusting for well-established prognostic factors including cytogenetic abnormalities, International Staging System (ISS), and Revised ISS (R-ISS). In addition, it showed significant prognostic associations in patient subsets stratified by these conventional prognostic factors. Importantly, CGS demonstrated a better performance in identifying high-risk patients compared to the GEP70 and SKY92 signatures, which have been recommended for prognostic stratification in MM. Moreover, CGS can further stratify patients into subgroups with significantly differential prognoses when applied to the high-risk and low-risk groups already identified by GEP70 and SKY92. The higher CGS score of patients is significantly associated with poor response to dexamethasone, a commonly used drug for MM treatment.<br \/>Conclusions: In summary, we proposed a computational framework that only requires gene expression data to identify clonal gene signatures for prognosis prediction. The CGS provides a useful biomarker for improving prognostic stratification in MM, especially for the identification of patients with the highest risk. The computational framework used for defining this signature provides a useful tool, which can be readily applied to many other cancer types.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Multiple myeloma,Prognostic gene signature,Computational biology,Drug resistance,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>J.-R. Li<\/b>, C. Wang, C. Cheng; <br\/>Baylor College of Medicine, Houston, TX","CSlideId":"","ControlKey":"1ee2a6fc-bcf0-4b00-bd84-e20827371fda","ControlNumber":"4814","DisclosureBlock":"&nbsp;<b>J. Li, <\/b> None..<br><b>C. Wang, <\/b> None..<br><b>C. Cheng, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2429","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"23","PosterboardNumber":"24","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7663","PresenterBiography":null,"PresenterDisplayName":"Jian-Rong Li, PhD","PresenterKey":"9a6d9090-c3be-4fd2-823b-bb5aa82603f2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7663. Identification of high-risk patients in multiple myeloma using a clonal gene signature","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Identification of high-risk patients in multiple myeloma using a clonal gene signature","Topics":null,"cSlideId":""},{"Abstract":"Introduction: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that disproportionately affects BRCA1 mutation carriers and young Black\/African American (AA) women. Black\/AA patients have the highest mortality and the shortest survival of any racial\/ethnic group in the US. With the approval of pembrolizumab, the addition of immune checkpoint blockade (ICB) to neoadjuvant chemotherapy (NACT) has become the standard of care (SOC) for high-risk early-stage TNBC. The pathologic complete response (pCR) is a reliable prognostic marker that correlates with tumor remission and good outcome, whereas pathologic incomplete response (pIR) with high residual cancer burden (RCB) is often associated with early relapse, treatment resistance, and poor survival. Many similarly-treated patients with identical TNM and RCB classifications still experience racial disparity, different relapse rates, and disparate survival. Current methods fall short in predicting tumor recurrence\/chemo-resistance\/patient survival with high accuracy in the clinic.<br \/>Methods: We detected a major racial disparity in our large regional cohorts of TNBC patients (&#62; 1,000 patients), of which 48% patients are Black\/AA and 48% patients are white patients, at the Sentara Cancer Network and VCU Massey Comprehensive Cancer Center, that have historically provided excellent healthcare and quality cancer care to the social-economically-disadvantaged, medically underserved, and underinsured racial\/ethnic minorities in low income communities in Virginia. Despite Sentara\/VCU&#8217;s best efforts, Black\/AA breast cancer patients still suffer 70-100% higher MBC mortality, and the worst survival compared to their white counterparts, based on our clinical studies and the SEER\/CDC databases.<br \/>Result: We showed that persistent EGFR\/RAS\/SIAH pathway activation is a major driving force of TNBC malignancy. The most downstream and evolutionarily conserved signaling gatekeeper, SIAH, is an RING domain E3 ligase that is a high-resolution prognostic biomarker for patient risk stratification and racial disparity prediction in TNBC. High SIAH expression in residual tumors reflects ineffective NACT\/IO therapy and persistent EGFR\/K-RAS\/SIAH pathway activation (ON) that drives tumor relapse, resistance, and reduced survival. Low SIAH expression in residual tumors reflects effective NACT\/IO therapy and EGFR\/K-RAS\/SIAH pathway inactivation (OFF) that predicts tumor remission, good outcome, and prolonged survival. We found that SIAH expression is 2.0-fold higher in Black\/AA patients&#8217; residual tumors than in the white patients&#8217; residual tumors, mirroring a 1.8-2.0-fold higher death rates in the Black\/AA patients than the white patients.<br \/>Conclusion: In this study, we demonstrate the prognostic power of SIAH for patient risk stratification, therapy quantification, and relationship to cancer racial disparity in TNBC.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Race,,Recurrence,Resistance,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>A. H. Tang<\/b><sup>1<\/sup>, R. A. Hoefer<sup>2<\/sup>, M. L. Guye<sup>3<\/sup>, B. Samli<sup>4<\/sup>, J. S. Winston<sup>4<\/sup>, J. Koblinski<sup>5<\/sup>, V. Robila<sup>5<\/sup>, M. O. Idowu<sup>5<\/sup>, R. J. Jansen<sup>6<\/sup>, H. D. Bear<sup>5<\/sup>; <br\/><sup>1<\/sup>Eastern Virginia Medical School, Norfolk, VA, <sup>2<\/sup>Sentara Cancer Network, Norfolk, VA, <sup>3<\/sup>Sentara Surgery Specialists, Newport News, VA, <sup>4<\/sup>Sentara Norfolk General Hospital, Norfolk, VA, <sup>5<\/sup>Virginia Commonwealth University, Richmond, VA, <sup>6<\/sup>University of Minnesota, Minneapolis, MN","CSlideId":"","ControlKey":"d849e10a-e3dd-45b4-b65f-eb40895d42a1","ControlNumber":"3483","DisclosureBlock":"&nbsp;<b>A. H. Tang, <\/b> None..<br><b>R. A. Hoefer, <\/b> None..<br><b>M. L. Guye, <\/b> None..<br><b>B. Samli, <\/b> None..<br><b>J. S. Winston, <\/b> None..<br><b>J. Koblinski, <\/b> None..<br><b>V. Robila, <\/b> None..<br><b>M. O. Idowu, <\/b> None..<br><b>R. J. Jansen, <\/b> None..<br><b>H. D. Bear, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2430","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"24","PosterboardNumber":"25","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7664","PresenterBiography":null,"PresenterDisplayName":"Amy Tang, PhD","PresenterKey":"3f47c5bd-468a-44f1-8a6e-541a49a7fb47","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7664. Early detection of racial disparity and treatment resistance in triple negative breast cancer","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Early detection of racial disparity and treatment resistance in triple negative breast cancer","Topics":null,"cSlideId":""},{"Abstract":"<b>Background: <\/b> Hepatocellular carcinoma (HCC) is the third leading cause of cancer death globally. Recurrence risks following curative resection remain high, ~50% after three years and 75-100% over five years. A biomarker for HCC recurrence is urgently needed to help lead treatment strategies. We previously showed that hepatic &#947;-hydroxy-1, N<sup>2<\/sup>-propano-2&#8242;-deoxyguanosine (&#947;-OHPdG), a DNA adduct derived from lipid peroxidation, increased during hepatocarcinogenesis. Furthermore, in a retrospective study, higher &#947;-OHPdG levels in post-surgical liver tumor tissues were associated with poorer survival (p&#60;0.0001) and shorter recurrence-free survival (p=0.007), suggesting that it may be a prognostic biomarker for HCC (Hepatology 2018). In this study, we aimed to test &#947;-OHPdG detected in livers after curative resection as a recurrence biomarker in a prospective study and, in addition, we developed a new non-invasive method for &#947;-OHPdG in circulating tumor cells (CTCs). This multicenter study seeks to validate &#947;-OHPdG as a biomarker for HCC recurrence.<br \/><b>Methods: <\/b> A total of 28 HCC patients undergoing hepatectomy at MedStar\/Georgetown University Hospital, Johns Hopkins University Hospital, and the University of Maryland Medical Center were enrolled. &#947;-OHPdG was detected in DNA isolated from hepatic tumors and non-tumors by a previous liquid chromatograph-tandem mass spectrometry (LC-MS\/MS) method and in HCC CTCs isolated from blood samples. CTCs were isolated using hepatocyte-specific rabbit anti-asialoglycoprotein-1 (ASGPR-1), followed by staining with mouse anti-&#947;-OHPdG antibodies. Clinical outcomes were correlated with &#947;-OHPdG in liver tissues and CTCs.<br \/><b>Results: <\/b> In our current cohort of 28 patients (mean age: 64.7 years; 82% male), five patients experienced HCC recurrence, with an estimated progression-free survival (PFS) rate of 85% over 8 months. &#947;-OHPdG levels (adducts\/10<sup>9<\/sup> nucleotides)<sup> <\/sup>detected by LC-MS\/MS varied widely in tumor tissues (5-56, mean: 11.8) and non-tumor tissue (7-71, mean: 20.6). Preliminary analysis showed shorter PFS associated with &#947;-OHPdG in non-tumors (cutoff: 16, p=0.0271). &#947;-OHPdG (arbitrary units x10<sup>7<\/sup>) in CTCs also varied widely in the nucleus (0.95-18.84, mean: 2.85) and in the whole cell (0.16- 52.18, mean: 9.72). Total CTC &#947;-OHPdG intensity in both the nucleus (p=0.006) and in the whole cell (p=0.005) was associated with its levels in non-tumor tissue. Furthermore, a shorter PFS was associated with CTC count (cutoff: 270 cells, p=0.01), and total CTC whole cell &#947;-OHPdG intensity (cutoff: 21.17x10<sup>7 <\/sup>arbitrary units, p=0.002).<br \/><b>Conclusion:<\/b> Preliminary results suggest that &#947;-OHPdG, measured in tissues by LC-MS\/MS and in blood by CTC,<b> <\/b>predicts HCC recurrence. Once evaluated in all enrolled subjects, multiple variant analyses will be carried out to include stage, AFP, grade of differentiation, vascular invasion on surgical samples, and status of viral hepatitis infection.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Hepatocellular carcinoma,Circulating tumor cells,Gamma-OHPdG,LC-MS\/MS,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"M. Kuo<sup>1<\/sup>, M. Aktop<sup>1<\/sup>, E. Ghabi<sup>2<\/sup>, M. A. Ouf<sup>1<\/sup>, M. Carder<sup>3<\/sup>, V. Muralidaran<sup>1<\/sup>, J. Ascue<sup>1<\/sup>, M. Hlouskova<sup>3<\/sup>, P. Wu<sup>2<\/sup>, G. Cheng<sup>4<\/sup>, S. S. Hecht<sup>4<\/sup>, H.-B. Fang<sup>1<\/sup>, N. Hanna<sup>3<\/sup>, J. He<sup>2<\/sup>, A. H. Kroemer<sup>1<\/sup>, M. Aggarwal<sup>1<\/sup>, A. R. He<sup>1<\/sup>, <b>F.-L. Chung<\/b><sup>1<\/sup>; <br\/><sup>1<\/sup>Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, <sup>2<\/sup>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, <sup>3<\/sup>University of Maryland Medical Center, Baltimore, MD, <sup>4<\/sup>Masonic Cancer Center, University of Minnesota, Minneapolis, MN","CSlideId":"","ControlKey":"660be8d3-2289-41a1-b068-a377b27c25f7","ControlNumber":"6968","DisclosureBlock":"&nbsp;<b>M. Kuo, <\/b> None..<br><b>M. Aktop, <\/b> None..<br><b>E. Ghabi, <\/b> None..<br><b>M. A. Ouf, <\/b> None..<br><b>M. Carder, <\/b> None..<br><b>V. Muralidaran, <\/b> None..<br><b>J. Ascue, <\/b> None..<br><b>M. Hlouskova, <\/b> None..<br><b>P. Wu, <\/b> None..<br><b>G. Cheng, <\/b> None..<br><b>S. S. Hecht, <\/b> None..<br><b>H. Fang, <\/b> None..<br><b>N. Hanna, <\/b> None..<br><b>J. He, <\/b> None..<br><b>A. H. Kroemer, <\/b> None..<br><b>M. Aggarwal, <\/b> None..<br><b>A. R. He, <\/b> None..<br><b>F. Chung, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2431","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"25","PosterboardNumber":"26","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7665","PresenterBiography":null,"PresenterDisplayName":"Fung-Lung Chung, PhD","PresenterKey":"813b1763-66a8-4876-8f90-33426c878866","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7665. Detection of &#947;-OHPdG as a hepatocellular carcinoma recurrence biomarker by CTCs and LC-MS\/MS","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Detection of &#947;-OHPdG as a hepatocellular carcinoma recurrence biomarker by CTCs and LC-MS\/MS","Topics":null,"cSlideId":""},{"Abstract":"Background Type XVII collagen is a membrane-associated collagen with interrupted triple-helices (MACIT) facilitating adhesion between the basement membrane (BS) and epithelial cells. Mutations in <i>COL17A1<\/i> lead to junctional epidermolysis bullosa (JEB), while autoimmunity against type collagen XVII ectodomain can cause bullous pemphigoid (BP). In multiple epithelial cancers, both type XVII collagen and its shed ectodomain are associated with cancer development and invasiveness. This study aims to assess the potential of type XVII collagen as an epithelial damage biomarker in patients with metastatic colorectal cancer (mCRC) and in patients with skin diseases like atopic dermatitis (AD) and psoriasis. Methodology Type XVII collagen ectodomain levels were measured in serum using a competitive ELISA (nordicPRO-C17). The study included two cohorts: cohort 1 comprised 212 patients with mCRC and 28 healthy controls and cohort 2 included patients with AD (n=8) or psoriasis (n=3). PRO-C17 levels in mCRC patients were compared to 28 healthy controls using a t-test. The association between PRO-C17 levels and overall survival (OS) was evaluated by categorizing patients into low PRO-C17 levels (tertiles 1+2) and high PRO-C17 levels (tertile 3). Kaplan-Meier curves and the log-rank test were used to assess differences in survival between the two groups. The independent predictive value of PRO-C17 was evaluated using multivariate Cox analysis. PRO-C17 levels in AD and psoriasis patients were compared to 15 healthy controls using one-way ANOVA, followed by multiple comparisons with Dunn's test. Results PRO-C17 levels were elevated (p&#60;0.05) in mCRC patients treated with bevacizumab compared to healthy controls. Patients with high PRO-C17 levels had a shorter overall survival (390 days) compared to those with low levels (539 days) (p=0.007). High levels of the biomarker were associated with an increased risk of mortality and PRO-C17 levels were independent of other risk factors, such as the number of drugs in the treatment regimen, tumor location, synchronous metastatic disease, primary tumor resection, performance status, and the number of metastatic sites (HR=1.43, 95% CI 1.01-2.01, p=0.044). Further, patients with AD had increased PRO-C17 levels (p=0.0057), while patients with psoriasis showed no significant differences in biomarker levels compared to healthy controls (p=0.58). Conclusions This study demonstrated that high PRO-C17 levels were independently associated with shorter OS and an increased risk of mortality in patients with mCRC. Additionally, elevated levels of PRO-C17 were observed in patients with AD. These findings suggest that type XVII collagen may serve as a reflection of epithelial damage in the invasive front during tumor metastasis. The role of this biomarker in other cancer types and skin diseases warrants further exploration.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Biomarkers,Colorectal cancer,Collagen,Prognostic markers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>M. Crespo-Bravo<\/b><sup>1<\/sup>, N. N. Nissen<sup>1<\/sup>, R. S. Pedersen<sup>1<\/sup>, M. K. Boisen<sup>2<\/sup>, M. Liljefors<sup>3<\/sup>, A. Z. Johansen<sup>2<\/sup>, J. S. Johansen<sup>2<\/sup>, M. A. Karsdal<sup>1<\/sup>, N. Willumsen<sup>1<\/sup>; <br\/><sup>1<\/sup>Nordic Bioscience, Herlev, Denmark, <sup>2<\/sup>Copenhagen University Hospital ‚Äì Herlev and Gentofte, Herlev, Denmark, <sup>3<\/sup>Intervention and Technology, Karolinska University Hospital Huddinge, Stockholm, Sweden","CSlideId":"","ControlKey":"3ccedb57-ed6d-4811-a7c6-b8db809c5b9d","ControlNumber":"2221","DisclosureBlock":"&nbsp;<b>M. Crespo-Bravo, <\/b> None.&nbsp;<br><b>N. N. Nissen, <\/b> <br><b>Nordic Bioscience<\/b> Employment.<br><b>R. S. Pedersen, <\/b> None..<br><b>M. K. Boisen, <\/b> None..<br><b>M. Liljefors, <\/b> None..<br><b>A. Z. Johansen, <\/b> None..<br><b>J. S. Johansen, <\/b> None.&nbsp;<br><b>M. A. Karsdal, <\/b> <br><b>Nordic Bioscience<\/b> Employment, Stock, Stock Option, Other Business Ownership, Grant\/Contract, Patent, Trademark, Other Intellectual Property. <br><b>N. Willumsen, <\/b> <br><b>Nordic Bioscience<\/b> Employment, Stock.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2432","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"26","PosterboardNumber":"27","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7666","PresenterBiography":null,"PresenterDisplayName":"Marina Crespo-Bravo, MS","PresenterKey":"aee91e16-9b02-4617-8a1b-0465769b086f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7666. Type XVII collagen as potential biomarker of epithelial damage in patients with atopic dermatitis and patients with metastatic colorectal cancer","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Type XVII collagen as potential biomarker of epithelial damage in patients with atopic dermatitis and patients with metastatic colorectal cancer","Topics":null,"cSlideId":""},{"Abstract":"Background: Neutrophil to lymphocyte ratio (NLR) has been reported as a prognostic biomarker in non-small cell lung cancer (NSCLC), while its biological rationale has yet to be clarified. In cancer patients, inflammation and immune status plays crucial roles in tumor growth and the prognosis. While several studies have explored the relationship between NLR and inflammation, there are few reports on the relationship between NLR and immune status in the tumor microenvironment of cancer patient so far. The purpose of this study is to explore the potential utility of NLR as a surrogate biomarker for assessing the immune response to tumors.<br \/>Methods: The medical records of NSCLC patients who underwent surgery at our institution in 2012 were retrospectively reviewed. The patients&#8217; clinical information including age, sex, performance status, smoking history, histology, clinical stage (7th), and NLR, was obtained. NLR was calculated based on blood tests conducted within a month before surgery. Tumor immune status was evaluated by Immunohistochemical staining for CD3, CD8, and FOXP3 in their surgical specimens. The relationship between NLR, clinicopathology, and tumor immune status was examined. The survival curves were estimated using the Kaplan-Meier method and compared using the log-rank test. Blood cell counts and ratios between different groups were compared using nonpaired t test or Mann-Whitney U test, with a significance threshold set at p = 0.05.<br \/>Results: A total of 120 patients were included. The 5-year overall survival rate (OS) in all 120 patients was 63.4%. The 5-year OS of the patients with lower NLR was significantly better than those with high NLR (low &#60; 2.2 vs high &#8805; 2.2; 70.1% vs 56.8%, p = 0.042). The 5-year OS of the patients with high density of CD3+ TILs was significantly better than that in patients with low density of CD3+ TILs (high &#8805; 242 vs low &#60; 242; 70% vs 56.8%, p = 0.019). The 5-year OS of the patients with high density of CD8+ TILs was significantly better than that in patients with low density of CD8+ TILs (high &#8805; 112 vs low &#60; 112; 72.4% vs 54.1%, p = 0.011). Conversely, the 5-year OS of the patients with low density of FOXP3+ TILs was significantly better than that in patients with high density of FOXP3+ TILs (high &#8805; 7.5 vs low &#60; 7.5; 46.2.% vs 79.6%, p = 0.0006). The number of CD3+ TILs had negative correlation with NLR (p = 0.005), while the number of CD8+ TILs and FOXP3+ TILs didn&#8217;t exhibit an association with NLR.<br \/>Conclusion: Our results suggest that NLR might potentially reflect immune status in the tumor microenvironment, explaining its impact on the prognosis of NSCLC patients. While further research is needed, these findings may offer valuable insights for guiding treatment options.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"NSCLC,Biomarkers,Tumor infiltrating lymphocytes,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>R. Yoshichika<\/b><sup>1<\/sup>, K. Iwata<sup>1<\/sup>, K. Suzawa<sup>2<\/sup>, Y. Thu<sup>1<\/sup>, D. Mizuno<sup>1<\/sup>, T. Higashihara<sup>1<\/sup>, N. Hayashi<sup>1<\/sup>, A. Matsuoka<sup>1<\/sup>, M. Yoshikawa<sup>1<\/sup>, F. Mukohara<sup>1<\/sup>, K. Shien<sup>2<\/sup>, H. Yamamoto<sup>2<\/sup>, S. Toyooka<sup>1<\/sup>; <br\/><sup>1<\/sup>Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, <sup>2<\/sup>Okayama University Hospital, Okayama, Japan","CSlideId":"","ControlKey":"4b05149e-c7bf-48eb-96d8-c2a5d9b4bee3","ControlNumber":"4491","DisclosureBlock":"&nbsp;<b>R. Yoshichika, <\/b> None..<br><b>K. Iwata, <\/b> None..<br><b>K. Suzawa, <\/b> None..<br><b>Y. Thu, <\/b> None..<br><b>D. Mizuno, <\/b> None..<br><b>T. Higashihara, <\/b> None..<br><b>N. Hayashi, <\/b> None..<br><b>A. Matsuoka, <\/b> None..<br><b>M. Yoshikawa, <\/b> None..<br><b>F. Mukohara, <\/b> None..<br><b>K. Shien, <\/b> None..<br><b>H. Yamamoto, <\/b> None..<br><b>S. Toyooka, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2433","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"27","PosterboardNumber":"28","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7667","PresenterBiography":null,"PresenterDisplayName":"Ryo Yoshichika, MD","PresenterKey":"4ba2dcb1-81f5-4f5f-8aa0-4ef525286c01","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7667. Neutrophil to lymphocyte ratio (NLR) as an indicator of tumor immune status in non-small cell lung cancer","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Neutrophil to lymphocyte ratio (NLR) as an indicator of tumor immune status in non-small cell lung cancer","Topics":null,"cSlideId":""},{"Abstract":"Background: The prognostic value of an effective biomarker, Pan-Immune-Inflammation Value (PIV), for head and neck squamous cell carcinoma (HNSCC) patients after radical surgery or chemoradiotherapy has not been well explored. This study aimed to construct and validate nomograms based on PIV to predict survival outcomes of HNSCC patients.<br \/>Methods:<i> <\/i>161 HNSCC patients underwent radical surgery and 50 patients received chemoradiotherapy were enrolled retrospectively for development and external validation cohort, respectively. The cut-off of PIV was determined using the maximally selected rank statistics method. Multivariable Cox regression and least absolute shrinkage and selection operator (LASSO) regression analyses were performed to develop two nomograms (Model A and Model B) that predict disease-free survival (DFS).<br \/>Results: Patients with higher PIV (&#8805;123.3) experienced a worse DFS (HR: 5.01, 95% CI: 3.25-7.72, <i>p<\/i>&#60;0.0001) and overall survival (OS) (HR: 5.23, 95% CI: 3.34-8.18, <i>p<\/i>&#60;0.0001) compared to patients with lower PIV (&#60;123.3), which was also consistent in the external cohort. Predictors of Model A included age, TNM stage, neutrophil-to-lymphocyte ratio (NLR) and PIV, and that of Model B included TNM stage, lymphocyte-to-monocyte ratio (LMR) and PIV. In comparison with TNM stage alone, the concordance index (C-index), receiver operating characteristic (ROC) curves and calibration curves of the nomograms demonstrated good calibration and discrimination, and the decision curve analysis (DCA) also showed satisfactory clinical utility in both internal and external validation.<br \/>Conclusions: The nomograms based on PIV, a simple but forceful indicator, can provide intuitive and precise prognosis prediction of individual HNSCC patients after radical surgery or chemoradiotherapy.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Prognostic markers,Survival,Surgical resection,Chemotherapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>Q. Chen<\/b>, X. Li, Y. Bai, Y. Chen; <br\/>The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China","CSlideId":"","ControlKey":"5a1eaa8f-180f-4de7-813d-c8a832a3ef68","ControlNumber":"4292","DisclosureBlock":"&nbsp;<b>Q. Chen, <\/b> None..<br><b>X. Li, <\/b> None..<br><b>Y. Bai, <\/b> None..<br><b>Y. Chen, <\/b> None.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2434","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"28","PosterboardNumber":"29","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7668","PresenterBiography":null,"PresenterDisplayName":"Qian Chen, BS","PresenterKey":"b91305b5-3443-4605-956c-f4a42a0b75cd","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7668. Novel pretreatment nomograms based on pan-Immune-inflammation value for predicting clinical outcome in patients with head and neck squamous cell carcinoma","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Novel pretreatment nomograms based on pan-Immune-inflammation value for predicting clinical outcome in patients with head and neck squamous cell carcinoma","Topics":null,"cSlideId":""},{"Abstract":"<b>Background:<\/b> Current tools for predicting prostate cancer biochemical recurrence (BCR) after RP often depend on parameters determined by pathologists, such as tumor grade, which is known to vary between reviewers. Genomic risk classifiers provide useful information but require substantial tissue, are costly, and are not commonly accessible in many medical centers. The study presents an artificial intelligence (AI) model for automated risk assessment of biochemical recurrence (BCR) by analyzing nuclear morphologic patterns from Pca archival H&#38;E slides. Nuclear morphometric features are essential for disease diagnosis and gaining insights into cellular functions. Specifically, we sought to evaluate whether the computational pathology approach could provide additional granular risk stratification within the low-risk group identified by Decipher.<br \/><b>Methods:<\/b> The study employed two cohorts from the University of Pennsylvania D<sub>1<\/sub> and D<sub>2<\/sub>. D<sub>1 <\/sub>comprised 180 patients, while D<sub>2 <\/sub>comprised 175 patients, including 63 individuals from the Decipher low-risk group. None of the patients in either cohort had received any pre-operative treatments. Within the Decipher cohort, a tumor segmentation model was created using the U-net deep learning network. The HoVer-Net model was used to both segment and classify nuclei. The feature extracted included a combination of nuclear texture and quantitative measurements of the spatial arrangement of nuclei. The eleven most significant features, selected via the least absolute shrinkage and selection operator (LASSO), were utilized to build a Cox regression model for predicting the risk of BCR in D<sub>1<\/sub>. In D<sub>2<\/sub>, patients were classified as either low-risk or high-risk for BCR based on the median risk score derived from D<sub>1<\/sub>.<br \/><b>Results: <\/b> Patients from D<sub>1 <\/sub>identified as high risk by the AI model experienced shorter survival, with a median BCR time of 27 months, in contrast to 55 months for those classified as low risk. The AI model demonstrated significant prognostic value for BCR in both D<sub>1<\/sub> (HR = 6.82, 95% confidence interval [CI]: 3.54-13.12, p &#60; 0.0019), and D<sub>2<\/sub> (HR = 2.72, 95% CI: 1.53-4.82, p &#60; 0.0032). Furthermore, the model effectively stratified the Decipher low-risk group in D<sub>2 <\/sub>into distinct low and high-risk categories (HR = 4.52, 95% confidence interval [CI]: 1.70-12.05, p &#60; 0.0085). The most prognostic features identified included five related to nuclei shape diversity (Minor Axis Length, Eccentricity, Equivalent Diameter, Solidity, and Circularity) in conjunction with nine nuclear texture features.<br \/><b>Conclusions:<\/b> The AI model's findings suggest that a digital image-based prognostic classifier for prostate cancer could serve as an alternative or complementary method to molecular-based companion risk tests. Additional, independent multi-site and prospective validation of these findings are warranted.<b><\/b>","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-07 Prognostic biomarkers,,"},{"Key":"Keywords","Value":"Prostate cancer,Predictive biomarkers,Machine learning,Recurrence,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":null,"AttendeeRatingAvg":null,"AttendeeRatingCount":null,"AuthorBlock":"<b>K. Hammouda<\/b><sup>1<\/sup>, T. Pathak<sup>1<\/sup>, T. Mirtti<sup>2<\/sup>, P. Lal<sup>3<\/sup>, S. Gupta<sup>4<\/sup>, A. Madabhushi<sup>1<\/sup>; <br\/><sup>1<\/sup>Emory University, Atlanta, GA, <sup>2<\/sup>University of Helsinki, Helsinki, Finland, <sup>3<\/sup>Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>4<\/sup>The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH","CSlideId":"","ControlKey":"c370024d-45ab-49f0-a80f-c920e0764e98","ControlNumber":"6568","DisclosureBlock":"&nbsp;<b>K. Hammouda, <\/b> None..<br><b>T. Pathak, <\/b> None.&nbsp;<br><b>T. Mirtti, <\/b> <br><b>Aiforia Technologies Plc.<\/b> Other, Independent Contractor.<br><b>P. Lal, <\/b> None..<br><b>S. Gupta, <\/b> None.&nbsp;<br><b>A. Madabhushi, <\/b> <br><b>Picture Health<\/b> Other, He is an equity holder, and he serves on the advisory board. His technology has been licensed to Picture Health. <br><b>Elucid Bioimaging<\/b> Other, He is an equity holder, His technology has been licensed to Elucid Bioimaging.. <br><b>Inspirata Inc.<\/b> Other, He is an equity holder. He is also involved in 3 different R01 grants with Inspirata Inc. \u000d\u000a. <br><b>Takeda<\/b> Other, He serves on the advisory board. <br><b>SimBioSys<\/b> Other, He serves on the advisory board and consults. <br><b>AstraZeneca<\/b> Other, He also has sponsored research agreements. <br><b>Boehringer-Ingelheim<\/b> He also has sponsored research agreements. <br><b>Eli-Lilly<\/b> Other, He also has sponsored research agreements. <br><b>Bristol Myers-Squibb<\/b> Other, He also has sponsored research agreements. <br><b>Frederick National Laboratory Advisory Committee<\/b> Other, He also serves as a member for the Frederick National Laboratory Advisory Committee.\u000d\u000a.","End":"4\/10\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"2435","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":"cslide-player-enabled is not true","PositionInSession":"29","PosterboardNumber":"30","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"7669","PresenterBiography":null,"PresenterDisplayName":"Kamal Hammouda","PresenterKey":"59ec5184-a484-42cd-b2b2-c1a9804ad2e8","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"7669. Use of computational pathology to predict biochemical recurrence in prostate cancer (Pca) (Rp) patients following radical prostatectomy: Evaluation in low decipher risk category","SearchResultFooter":"","SearchResultHeader":"Apr 10 2024  9:00AM","SessionId":"236","SessionOnDemand":"False","SessionTitle":"Prognostic Biomarkers 2","ShowChatLink":"false","Start":"4\/10\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Use of computational pathology to predict biochemical recurrence in prostate cancer (Pca) (Rp) patients following radical prostatectomy: Evaluation in low decipher risk category","Topics":null,"cSlideId":""}]